CA2374788A1 - Inhibitors of factor xa - Google Patents

Inhibitors of factor xa Download PDF

Info

Publication number
CA2374788A1
CA2374788A1 CA002374788A CA2374788A CA2374788A1 CA 2374788 A1 CA2374788 A1 CA 2374788A1 CA 002374788 A CA002374788 A CA 002374788A CA 2374788 A CA2374788 A CA 2374788A CA 2374788 A1 CA2374788 A1 CA 2374788A1
Authority
CA
Canada
Prior art keywords
group
4alkyl
ring
independently
member selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002374788A
Other languages
French (fr)
Inventor
Bing-Yan Zhu
Robert M. Scarborough
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
COR Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by COR Therapeutics Inc filed Critical COR Therapeutics Inc
Publication of CA2374788A1 publication Critical patent/CA2374788A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
    • C07C311/46—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

Compounds, e.g. described in Table (1), their salts and compositions related thereto having activity against mammalian factor Xa are disclosed. The compounds are useful <i>in vitro</i> or <i>in vivo</i> for preventing or treating coagulation disorders.

Description

INHIBITORS OF FACTOR Xa Related Applications This application claims benefit of priority under 35 USC ~ 119(e) to U.S.
Provisional Application No. 60/135,838 filed on May 24, 1999, which is herein incorporated in its entirety by reference.
Field of the Invention This invention relates to novel compounds which are potent and highly selective inhibitors of isolated factor Xa or when assembled in the prothrombinase complex..-These compounds show selectivity for factor Xa versus other proteases of the coagulation (e.g. thrombin, fVIIa, flXa) or the fibrinolytic cascades (e.g.
plasminogen activators, plasmin). In another aspect, the present invention relates to novel monoamidino-containing compounds, their pharmaceutically acceptable salts, and pharmaceutically acceptable compositions thereof which are useful as potent ' and specific inhibitors of blood coagulation in mammals. In yet another aspect, the invention relates to methods for using these inhibitors as therapeutic agents for disease states in mammals characterized by coagulation disorders.
Background of the Invention Hemostasis, the control of bleeding, occurs by surgical means, or by the . physiological properties of vasoconstriction and coagulation. This invention is particularly concerned with blood coagulation and ways in which it assists in maintaining the integrity of mammalian circulation after injury, inflammation, disease, congenital defect, dysfunction or other disruption. Although platelets and blood coagulation are both involved in thrombus formation, certain components of the coagulation cascade are primarily responsible for the amplification or acceleration of the processes involved in platelet aggregation and fibrin deposition.
Thrombin is a key enzyme in the coagulation cascade as well as in hemostasis. Thrombin plays a central role in thrombosis through its ability to catalyze the conversion of fibrinogen into fibrin and through its potent platelet activation activity. Direct or indirect inhibition of thrombin activity has been the focus of a variety of recent anticoagulant strategies as reviewed by Claeson, G., "Synthetic Peptides and Peptidomimetics as Substrates and Inhibitors of Thrombin and Other Proteases in the Blood Coagulation System", Blood Coag. Fibrinol.
_5, 411-436 (1994). Several classes of anticoagulants currently used in the clinic directly or indirectly affect thrombin (i.e. heparins, low-molecular weight heparins, heparin-like compounds and coumarins).
A prothrombinase complex, including Factor Xa (a serine protease, the activated form of its Factor X precursor and a member of the calcium ion binding, gamma carboxyglutamyl (Gla)-containing, vitamin K dependent, blood coagulation glycoprotein family), converts the zymogen prothrombin into the active procoagulant thrombin. Unlike thrombin, which acts on a variety of protein substrates as well as at a specific receptor, factor Xa appears to have a single physiologic substrate, namely prothrombin. Since one molecule of factor Xa may be able to generate up to 138 molecules of thrombin (Elodi et al., Thromb. Res.
15, 61~7-619 (1979)); direct inhibition of factor Xa as a way of indirectly inhibiting the formation of thrombin may be an efficient anticoagulant strategy. Therefore, it has been suggested that compounds which selectively inhibit factor Xa may be useful as in vitro diagnostic agents, or for therapeutic administration in certain thrombotic disorders, see e.g., WO 94/13693.
Polypeptides derived from hematophagous organisms have been reported which are highly potent and specific inhibitors of factor Xa. United States Patent 4,588,587 describes anticoagulant activity in the saliva of the Mexican leech, Haementeria o~cinalis. A principal component of this saliva was shown to be the polypeptide factor Xa inhibitor, antistasin (ATS), by Nutt, E. et al., "The Amino Acid Sequence of Antistasin, a Potent Inhibitor of Factor Xa Reveals a Repeated Internal Structure", J. Biol. Chem., 263, 10162-10167 (1988). Another potent and highly specific inhibitor of Factor Xa, called tick anticoagulant peptide (TAP), has been isolated from the whole body extract of the soft tick Ornithidoros moubata, as reported by Waxman, L., et al., "Tick Anticoagulant Peptide (TAP) is a Novel Inhibitor of Blood Coagulation Factor Xa" Science, ~, 593-596 (1990).
Factor Xa inhibitory compounds which are not large polypeptide-type inhibitors have also been reported including: Tidwell, R.R. et al., "Strategies for Anticoagulation With Synthetic Protease Inhibitors. Xa Inhibitors Versus Thrombin Inhibitors", Thromb. Res., l~, 339-349 (1980); Turner, A.D. et al., "p-Amidino Esters as Irreversible Inhibitors of Factor IXa and Xa and Thrombin", Biochemistry, ~, 4929-4935 (1986); Hitomi, Y. et al., "Inhibitory Effect of New Synthetic Protease Inhibitor (FUT-175) on the Coagulation System", Haemostasis, ~, 164-168 (1985); Sturzebecher, J. et al., "Synthetic Inhibitors of Bovine Factor Xa and Thrombin. Comparison of Their Anticoagulant Efficiency", Thromb. Res., ~, 245-252 (1989); Kam, C.M. et al., "Mechanism Based Isocoumarin Inhibitors for Trypsin and Blood Coagulation Serine Proteases: New Anticoagulants", Biochemistry, ~, 2547-2557 (1988); Hauptmann, J. et al., "Comparison of the Anticoagulant and Antithrombotic Effects of Synthetic Thrombin and Factor Xa Inhibitors", Thromb. Haemost., ~3, 220-223 (1990); and the like.
Others have reported Factor Xa inhibitors which are small molecule organic compounds, such as nitrogen containing heterocyclic compounds which have amidino substituent groups, wherein two functional groups of the compounds can bind to Factor Xa at two of its active sites. For example, WO 98/28269 describes pyrazole compounds having a terminal C(=NH)-NHZ group; WO 97/21437 describes benzimidazole compounds substituted by a basic radical which are connected to a naththyl group via a straight or branched chain alkylene,-C(=O) or -S(=O)2 bridging group; WO 99/10316 describes compounds having a 4-phenyl-N-alkylamidino-piperidine and 4-phenoxy-N-alkylamidino-piperidine group connected to a 3-amidinophenyl group via a carboxamidealkyleneamino bridge; and EP 798295 describes compounds having a 4-phenoxy-N-alkylamidino-piperidine group connected to an amidinonaphthyl group via a substituted or unsubstituted sulfonamide or carboxamide bridging group.
There exists a need for effective therapeutic agents for the regulation of hemostasis, and for the prevention and treatment of thrombus formation and other pathological processes in the vasculature induced by thrombin such as restenosis and inflammation. In particular, there continues to be a need for compounds which selectively inhibit factor Xa or its precursors. Compounds that have different combinations of bridging groups and functional groups than compounds previously discovered are needed, particularly compounds which selectively or preferentially bind to Factor Xa. Compounds with a higher degree of binding to Factor Xa than to thrombin are desired, especially those compounds having good bioavailability and/or solubility.
Summarv of the Invention The present invention relates to novel compounds which inhibit factor Xa, their pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives, and pharmaceutically acceptable compositions thereof which have particular biological properties and are useful as potent and specific inhibitors of blood coagulation in mammals. In another aspect, the invention relates to methods of using these inhibitors as diagnostic reagents or as therapeutic agents for disease states in mammals which have coagulation disorders, such as in the treatment or , prevention of any thrombotically mediated acute coronary or cerebrovascular syndrome, any thrombotic syndrome occurnng in the venous system, any coagulopathy, and any thrombotic complications associated with extracorporeal circulation or instrumentation, and for the inhibition of coagulation in biological samples.
In certain embodiments, this invention relates to novel compounds which are potent and highly selective inhibitors of isolated factor Xa when assembled in the prothrombinase complex. These compounds show selectivity for factor Xa versus other proteases of the coagulation cascade (e.g. thrombin, etc.) or the fibrinolytic cascade, and are useful as diagnostic reagents as well as antithrombotic agents.
In a preferred embodiment, the present invention provides a compound of the formula I:
A-Y-D-E-G-J-Z-L
wherein:
A is selected from:
(a) C,-C6 alkyl;
(b) C3-C8 cycloalkyl;
(c) phenyl, which is independently substituted with 0-2 R' subsituents;
(d) naphthyl, which is independently substituted with 0-2 R' subsituents;and (e) a monocyclic or fused bicyclic heterocyclic ring system having from S to 10 ring atoms, wherein 1-4 ring atoms of the ring system are -$-selected from N, O and S, and wherein the ring system may be substituted with 0-2 R' subsituents;
R' is selected from:
Halo, C,~alkyl, Cz_6alkenyl, CZ_balkynyl, C3_acycloalkyl, Co~alkylC3_ gcycloalkyl,-CN, -NOz, (CHZ)mNRZR3, SOzNR2R3, SOZR2, CF3, OR2, and a S-6 membered aromatic heterocyclic system containing from 1-4 heteroatoms selected from N, O and S, wherein from 1-4 hydrogen atoms on the aromatic heterocyclic system may be independently replaced with a member selected from the group consisting of halo, C,-C4-alkyl, -CN C,~,alkyl, Cz_6alkenyl, Cz_ 6alkynyl, C3_8cycloalkyl, Co~alkylC3_8cycloalkyl and -NOZ;
RZ and R' are independently selected from the group consisting of H, C,~alkyl, Cz_balkenyl, CZ_6alkynyl, C3_8cycloalkyl, Co~,alkylC3_8cycloalkyl, Co~alkylphenyl and C~allcylnaphthyl, wherein from 1-4 hydrogen atoms on the ring atoms of the phenyl and naphthyl moieties may be independently replaced with a member selected from the group consisting of halo, C,~alkyl, CZ_6alkenyl, Cz_6alkynyl, C3_$cycloalkyl, C~alkylC3_8cycloalkyl, -CN, and -NOz m is an integer of 0-2;
Y is a member selected from the group consisting of a direct link, -C(=O)-, -N(R4)-, -C(=O)-N(R4)-, -N(R4)-C(=O)-, -SOz-, -O-, -SOZ-N(R4)- and N(R4)-SOZ ;
R4 is selected from:
H, C,~alkyl, Cz_6alkenyl, CZ_6alkynyl, C3_gcycloalkyl, Co~alkylC3_gcycloalkyl, Co~alkylphenyl and C~alkylnaphthyl, wherein from 1-4 hydrogen atoms on the ring atoms of the phenyl and naphthyl moieties may be independently replaced with a member selected from the group consisting of halo, C,~alkyl, CZ_6alkenyl, Cz_6alkynyl, C3_8cycloalkyl, Co~alkylC3_gcycloalkyl, -CN, and _NOz~.
D is a direct link or is a member selected from the group consisting of (a) phenyl, which is independently substituted with 0-2 R'a subsituents;

(b) naphthyl, which is independently substituted with 0-2 R'a subsituents;
and (c) a monocyclic or fused bicyclic heterocyclic ring system having from to 10 ring atoms, wherein 1-4 ring atoms of the ring system are 5 selected from N, O and S, and wherein the ring system may be substituted with 0-2 R'e subsituents;
R'a is selected from:
Halo, C,~,alkyl, Cz_6alkenyl, Cz_6alkynyl, C3_$cycloalkyl, C~alkylC3_ 8cycloalkyl, -CN, -NOz, (CHz)mNRzaR38, SOZNRzaR3a, SOZRze, CF3, ORze, and a 5-6 membered aromatic heterocyclic system containing from 1-4 heteroatoms selected from N, O and S, wherein from 1-4 hydrogen atoms on the aromatic heterocyclic system may be independently replaced with a member selected from the group consisting of halo, C,~alkyl, Cz_6alkenyl, Cz_ balkynyl, C3_8cycloalkyl, C~alkylC3_$cycloalkyl, -CN and -NOz.
Rza and R38 are independently selected from the group consisting of H, C,~allcyl, Cz_6alkenyl, Cz_6alkynyl, C3_8cycloalkyl, Co~alkylC3_gcycloalkyl, Co~alkylphenyl and C~alkylnaphthyl, wherein from 1-4 hydrogen atoms on the ring atoms of the phenyl and naphthyl moieties may be independently replaced with a member selected from the group consisting of halo, C,~alkyl, Cz_6alkenyl, Cz_balkynyl, C3_8cycloalkyl, Co~alkylC3_8cycloalkyl, -CN and _NOz~.
E is a member selected from the group consisting of -N(Rs)_C(=O)_, -C(=O)_N(RS)-, -N(RS)-C(-O)_N(R6)-, -SOz_N(RS)-, -N(RS)-SOz-N(R6)- and -N(RS)-SOz N(R6)-C(=O)-;
RS and R6 are independently selected from:
H, C,~alkyl, Cz_6alkenyl, Cz_6alkynyl, C3_gcycloalkyl, C~alkylC3_gcycloalkyl, C~alkylphenyl, Co~alkylnaphthyl, C~alkylheteroaryl, C,~alkylCOOH and C,~alkylCOOC,~alkyl, wherein from 1-4 hydrogen atoms on the ring atoms of the phenyl, naphthyl and heteroaryl moieties may be independently replaced with a member selected from the group consisting of halo, C,~alkyl, CZ_balkenyl, CZ_6alkynyl, C3_8cycloalkyl, C~alkylC3_$cycloalkyl, -CN and -NOz G is a member selected from the group consisting of:
a direct link, -CR'R$- and -CR'aRga-CR'aRgb-wherein R', R8, R'a, RBa, R'~ and R8b are independently a member selected from from the group consisting of hydrogen, C,_4alkyl, Cz_6alkenyl, Cz_6alkynyl, C3_8cycloalkyl, C°~alkyl-C3_ 8cycloalkyl, C°~alkylphenyl, C°~,alkylnaphthyl, -OR9, -C~,,alkylCOOR9, -Co-aalkylC(=O)NR9R'o, -Co-aalkYlC(=O)NR9-CHZ-CHZ O-R'°, -Co~alkylC(=O)NR9(-CHZ-CHz-O-R'°-)2, -N(R9)COR'°, -N(R9)C(=O)R'°, -N(R9)SOZR'°, and a naturally occurring or synthetic amino acid side chain, wherein from 1-4 hydrogen atoms on the ring atoms of the phenyl and naphthyl moieties may be independently replaced with a member selected from the group consisting of halo, C,~alkyl, CZ_6alkenyl, Cz_6alkynyl, C3_ 8cycloalkyl, C°~alkyl-C3_$cycloalkyl, -CN and -NOz;
R9 and R'° are independently selected from:
H, C,~,alkyl, C~alkylphenyl and C°~alkylnaphthyl, wherein from 1-4 hydrogen atoms on the ring atoms of the phenyl and naphthyl moieties may be independently replaced with a member selected from the group consisting of halo, C,~alkyl, CZ_6alkenyl, CZ_6alkynyl, C3_8cycloalkyl, Co~alkyl-C3_ gcycloalkyl, -CN and -NO2, and wherein R9 and R'° taken together can form a 5-8 membered heterocylic ring;
J is a member selected from the group consisting of Itta ~Rtt Dtta tt ,R
0-2 ~ ~r~2 and Rtt b Rtt b N' wherein the ring carbons or second ring nitrogen of the amino ring structure and/or the ring carbons on the alkylene bridging groups attached to the amino ring structure may be independently substituted by a total of 0 to 4 R", R"a, R"b and R"~
groups;

_$_ R", R"a, R"b and R"° are independently a member selected from the group consisting of hydrogen, -OH, -O-C,~alkyl, -C,~alkyl, CZ_6alkenyl, CZ_6alkynyl, C3_ 8cycloalkyl, C~alkyl-C,_$cycloalkyl, Co~alkylphenyl, Co~alkylnaphthyl, Co.~alkylheterocyclic ring having from 1 to 4 hetero ring atoms selected from the group consisting of N, O and S, CHZCOOC,~alkyl, CHZCOOC,~alkylphenyl and CHZCOOC,~alkylnaphthyl;
Z is a member selected from the group consisting of (a) phenyl, which is independently substituted with 0-2 R'b subsituents;
(b) naphthyl, which is independently substituted with 0-2 R'b subsituents;
and (c) a monocyclic or fused bicyclic heterocyclic ring system having from 5 to 10 ring atoms, wherein 1-4 ring atoms of the ring system are selected from N, O and S, and wherein the ring system may be substituted with 0-2 R'b subsituents;
R'b is selected from:
Halo, C,~alkyl, CZ_6alkenyl, CZ_6alkynyl, C3_$cycloalkyl, Co~alkylC3_ 8cycloalkyl, -CN, -NOz, NRZbR3b~ SOZNR2bR3b~ SOZRzb, CF3, ORZb, O-CHZ
CHZ-ORZb, O-CHZ-COORzb, N(RZb)-CHZ_CHz-ORzb, N(-CHZ-CHZ-ORZb)2, N(Rzb)-C(=O)R3b, N(RZb)-SOZ-R3b, and a 5-6 membered aromatic heterocyclic system containing from 1-4 heteroatoms selected from N, O and S, wherein from 1-4 hydrogen atoms on the aromatic heterocyclic system may be independently replaced with a member selected from the group consisting of halo, C,~alkyl, Cz_6alkenyl, CZ_6alkynyl, C3_8cycloalkyl, Co~alkylC3_ 8cycloalkyl, -CN and -NOZ;
RZb and R3b are independently selected from the group consisting of H, C,~alkyl, Cz_6alkenyl, Cz_6alk5myl, C3_8cycloalkyl, Co~alkylC3_$cycloallcyl, C~alkylphenyl and Co~alkylnaphthyl, wherein from 1-4 hydrogen atoms on the ring atoms of the phenyl and naphthyl moieties may be independently replaced with a member selected from the group consisting of halo, C,~alkyl, _g_ Cz_6alkenyl, Cz_6alkynyl, C3_$cycloalkyl, C~alkylC3_gcycloalkyl, -CN and _NOz L is selected from:
H~ _CN~ C~-O~yzRis~ ~CHz)~WzR~3~ L,~_~12~~12R13~ yzR~s~ OR'z, -yzC~-yz~yzR~3~ and NR'zC(=NR'z)-R's;
R'z and R'3 are independently selected from:
hydrogen, -OR'4, -NR'4R'S, C,~alkyl, Co~alkylphenyl, C~alkylnaphthyl, COOC,~alkyl, COO-Co~alkylphenyl and COO-Co~alkylnaphthyl, wherein from 1-4 hydrogen atoms on the ring atoms of the phenyl and naphthyl moieties may be independently replaced with a member selected from the group consisting of halo, C,~alkyl, Cz_6alkenyl, Cz_6alkynyl, C3_8cycloalkyl, Co~alkylC3_8cycloalkyl, -CN, and -NOz;
R'4 and R'S are independently selected from:
H, C,~,alkyl, Cz_6alkenyl, Cz_balkynyl, C3_$cycloalkyl, Co~alkylC3_gcycloalkyl, Co~alkylphenyl and Co..4alkylnaphthyl, wherein from 1-4 hydrogen atoms on the ring atoms of the phenyl and naphthyl moieties may be independently replaced with a member selected from the group consisting of halo, C,~alkyl, Cz_6alkenyl, Cz_6alk3myl, C3_gcycloalkyl, C~alkylC3_gcycloalkyl, -CN, and -NOz;
and all pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives thereof.
In certain aspects of this invention, compounds are provided which are useful as diagnostic reagents. In another aspect, the present invention includes pharmaceutical compositions comprising a pharmaceutically effective amount of the compounds of this invention and a pharmaceutically acceptable carrier. In yet another aspect, the present invention includes methods comprising using the above compounds and pharmaceutical compositions for preventing or treating disease states characterized by undesired thrombosis or disorders of the blood coagulation process in mammals, or for preventing coagulation in biological samples such as, for example, stored blood products and samples. Optionally, the methods of this invention comprise administering the pharmaceutical composition in combination with an additional therapeutic agent such as an antithrombotic and/or a thrombolytic agent and/or an anticoagulant.
The preferred compounds also include their pharmaceutically acceptable isomers, hydrates, solvates, salts and prodrug derivatives.
Detailed Description of the Invention Definitions In accordance with the present invention and as used herein, the following terms are defined with the following meanings, unless explicitly stated otherwise.
The term "alkenyl" refers to a trivalent straight chain or branched chain unsaturated aliphatic radical. The term "alkinyl" (or "alkynyl") refers to a straight or branched chain aliphatic radical that includes at least two carbons joined by a triple bond. If no number of carbons is specified alkenyl and alkinyl each refer to radicals , having from 2-12 carbon atoms.
The term "alkyl" refers to saturated aliphatic groups including straight-chain, branched-chain and cyclic groups having the number of carbon atoms specified, or if no number is specified, having up to 12 carbon atoms. The term "cycloalkyl" as used herein refers to a mono-, bi-, or tricyclic aliphatic ring having 3 to 14 carbon atoms and preferably 3 to 7 carbon atoms.
As used herein, the terms "carbocyclic ring structure " and " C3_,6 carbocyclic mono, bicyclic or tricyclic ring structure" or the like are each intended to mean stable ring structures having only carbon atoms as ring atoms wherein the ring structure is a substituted or unsubstituted member selected from the group consisting of a stable monocyclic ring which is aromatic ring ("aryl") having six ring atoms; a stable monocyclic non-aromatic ring having from 3 to 7 ring atoms in the ring;
a stable bicyclic ring structure having a total of from 7 to 12 ring atoms in the two rings wherein the bicyclic ring structure is selected from the group consisting of ring structures in which both of the rings are aromatic, ring structures in which one of the rings is aromatic and ring structures in which both of the rings are non-aromatic; and a stable tricyclic ring structure having a total of from 10 to 16 atoms in the three rings wherein the tricyclic ring structure is selected from the group consisting of ring structures in which three of the rings are aromatic, ring structures in which two of the rings are aromatic and ring structures in which three of the rings are non-aromatic. In each case, the non-aromatic rings when present in the monocyclic, bicyclic or tricyclic ring structure may independently be saturated, partially saturated or fully saturated. Examples of such carbocyclic ring structures include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, adamantyl, cyclooctyl, [3.3.0]bicyclooctane, [4.3.0]bicyclononane, [4.4.0]bicyclodecane (decalin), 2.2.2]bicyclooctane, fluorenyl, phenyl, naphthyl, indanyl, adamantyl, or tetrahydronaphthyl (tetralin). Moreover, the ring structures described herein may be attached to one or more indicated pendant groups via any carbon atom which results in a stable structure. The term "substituted" as used in conjunction with carbocyclic ring structures means that hydrogen atoms attached to the ring carbon atoms of ring structures described herein may be substituted by one or more of the substituents indicated for that structure if such substitutions) would result in a stable compound.
The term "aryl" which is included with the term "carbocyclic ring structure"
refers to an unsubstituted or substituted aromatic ring, substituted with one, two or three substituents selected from loweralkoxy, loweralkyl, loweralkylamino, hydroxy, halogen, cyano, hydroxyl, mercapto, nitro, thioalkoxy, carboxaldehyde, carboxyl, carboalkoxy and carboxamide, including but not limited to carbocyclic aryl, heterocyclic aryl, and biaryl groups and the like, all of which may be optionally substituted. Preferred aryl groups include phenyl, halophenyl, loweralkylphenyl, napthyl, biphenyl, phenanthrenyl and naphthacenyl.
The term "arylalkyl" which is included with the term "carbocyclic aryl"
refers to one, two, or three aryl groups having the number of carbon atoms designated, appended to an alkyl group having the number of carbon atoms designated. Suitable arylalkyl groups include, but are not limited to, benzyl, picolyl, naphthylmethyl, phenethyl, benzyhydryl, trityl, and the like, all of which may be optionally substituted.
As used herein, the term "heterocyclic ring" or "heterocyclic ring system" is intended to mean a substituted or unsubstituted member selected from the group consisting of stable monocyclic ring having from 5-7 members in the ring itself and having from 1 to 4 hetero ring atoms selected from the group consisting of N, O and S; a stable bicyclic ring structure having a total of from 7 to 12 atoms in the two rings wherein at least one of the two rings has from 1 to 4 hetero atoms selected from N, O and S, including bicyclic ring structures wherein any of the described stable monocyclic heterocyclic rings is fused to a hexane or benzene ring; and a stable tricyclic heterocyclic ring structure having a total of from 10 to 16 atoms in the three rings wherein at least one of the three rings has from 1 to 4 hetero atoms selected from the group consisting of N, O and S. Any nitrogen and sulfur atoms present in a heterocyclic ring of such a heterocyclic ring structure may be oxidized.
Unless indicated otherwise the terms "heterocyclic ring" or "heterocyclic ring system" include aromatic rings, as well as non-aromatic rings which can be saturated, partially saturated or fully saturated non-aromatic rings. Also, unless indicated otherwise the term "heterocyclic ring system" includes ring structures wherein all of the rings contain at least one hetero atom as well as structures having less than all of the rings in the ring structure containing at least one hetero atom, for example bicyclic ring structures wherein one ring is a benzene ring and one of the rings has one or more hetero atoms are included within the term "heterocyclic ring systems" as well as bicyclic ring structures wherein each of the two rings has at least one hetero atom. Moreover, the ring structures described herein may be attached to one or more indicated pendant groups via any hetero atom or carbon atom which results in a stable structure. Further, the term "substituted" means that one or more of the hydrogen atoms on the ring carbon atoms) or nitrogen atoms) of the each of the rings in the ring structures described herein may be replaced by one or more of the indicated substituents if such replacements) would result in a stable compound.
Nitrogen atoms in a ring structure may be quaternized, but such compounds are specifically indicated or are included within the term "a pharmaceutically acceptable salt" for a particular compound. When the total number of O and S atoms in a single heterocyclic ring is greater than 1, it is preferred that such atoms not be adjacent to one another. Preferably, there are no more that 1 O or S ring atoms in the same ring of a given heterocyclic ring structure.
Examples of monocylic and bicyclic heterocylic ring systems, in alphabetical order, are acridinyl, azocinyl, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazalinyl, carbazolyl, 4aH-carbazolyl, carbolinyl, chromanyl, chromenyl, cinnolinyl, decahydroquinolinyl, 2H,6H-1,5,2-dithiazinyl, dihydrofuro[2,3-b]tetrahydrofuran, furanyl, furazanyl, imidazolidinyl, imidazolinyl, imidazolyl, 1H-indazolyl, indolinyl, indolizinyl, indolyl, 3H-indolyl, isobenzofuranyl, isochromanyl, isoindazolyl, isoindolinyl, isoindolyl, isoquinolinyl (benzimidazolyl), isothiazolyl, isoxazolyl, morpholinyl, naphthyridinyl, octahydroisoquinolinyl, oxadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, oxazolidinyl, oxazolyl, oxazolidinyl, pyrimidinyl, phenanthridinyl, phenanthrolinyl, phenazinyl, phenothiazinyl, phenoxathiinyl, phenoxazinyl, phthalazinyl, piperazinyl, piperidinyl, pteridinyl, purinyl, pyranyl, pyrazinyl, pyroazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, pryidooxazole, pyridoimidazole, pyridothiazole, pyridinyl, pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolinyl, 2H-pyrrolyl, pyrrolyl, quinazolinyl, quinolinyl, 4H-quinolizinyl, quinoxalinyl, quinuclidinyl, tetrahydrofuranyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, 6H-1,2,5-thiadazinyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, thianthrenyl, thiazolyl, thienyl, thienothiazolyl, thienooxazolyl, thienoimidazolyl, thiophenyl, triazinyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl and xanthenyl. Preferred heterocyclic ring structures include, but are not limited to, pyridinyl, furanyl, thienyl, pyrrolyl, pyrazolyl, pyrrolidinyl, imidazolyl, indolyl, benzimidazolyl, 1H-indazolyl, oxazolinyl, or isatinoyl. Also included are fused ring and spiro compounds containing, for example, the above heterocylic ring structures.
As used herein the term "aromatic heterocyclic ring system" has essentially the same definition as for the monocyclic and bicyclic ring systems except that at least one ring of the ring system is an aromatic heterocyclic ring or the bicyclic ring has an aromatic or non-aromatic heterocyclic ring fused to an aromatic carbocyclic ring structure.
The terms "halo" or "halogen" as used herein refer to Cl, Br, F or I
substituents. The term "haloalkyl", and the like, refer to an aliphatic carbon radicals having at least one hydrogen atom replaced by a Cl, Br, F or I atom, including mixtures of different halo atoms. Trihaloalkyl includes trifluoromethyl and the like as preferred radicals, for example.
The term "methylene" refers to -CH2-.
The term "pharmaceutically acceptable salts" includes salts of compounds derived from the combination of a compound and an organic or inorganic acid.
These compounds are useful in both free base and salt form. In practice, the use of the salt form amounts to use of the base form; both acid and base addition salts are within the scope of the present invention.
"Pharmaceutically acceptable acid addition salt" refers to salts retaining the biological effectiveness and properties of the free bases and which are not biologically or otherwise undesirable, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, and organic acids such as acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, malefic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicyclic acid and the like.
"Pharmaceutically acceptable base addition salts" include those derived from inorganic bases such as sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts and the like.
Particularly preferred are the ammonium, potassium, sodium, calcium and magnesium salts.
Salts derived from pharmaceutically acceptable organic nontoxic bases include salts of primary, secondary, and tertiary amines, substituted amines including naturally occurnng substituted amines, cyclic amines and basic ion exchange resins, such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, 2-diethylaminoethanol, trimethamine, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline, betaine, ethylenediamine, glucosamine, methylglucamine, theobromine, purines, piperizine, piperidine, N-ethylpiperidine, polyamine resins and the like. Particularly preferred organic nontoxic bases are isopropylamine, diethylamine, ethanolamine, trimethamine, dicyclohexylamine, choline, and caffeine.
"Biological property" for the purposes herein means an in vivo effector or antigenic function or activity that is directly or indirectly performed by a compound of this invention that are often shown by in vitro assays. Effector functions include receptor or ligand binding, any enzyme activity or enzyme modulatory activity, any carrier binding activity, any hormonal activity, any activity in promoting or inhibiting adhesion of cells to an extracellular matrix or cell surface molecules, or any structural role. Antigenic functions include possession of an epitope or antigenic site that is capable of reacting with antibodies raised against it.
In the compounds of this invention, carbon atoms bonded to four non-identical substituents are asymmetric. Accordingly, the compounds may exist as diastereoisomers, enantiomers or mixtures thereof. The syntheses described herein may employ racemates, enantiomers or diastereomers as starting materials or intermediates. Diastereomeric products resulting from such syntheses may be separated by chromatographic or crystallization methods, or by other methods known in the art. Likewise, enantiomeric product mixtures may be separated using the same techniques or by other methods known in the art. Each of the asymmetric carbon atoms, when present in the compounds of this invention, may be in one of two configurations (R or S) and both are within the scope of the present invention.
Preferred Embodiments In a preferred embodiment, the present invention provides a compound according to the formula I:
A-Y-D-E-G-J-Z-L
wherein:
A is selected from:
(a) C,-C6 alkyl;
(b) C3-C$-cycloalkyl;
(c) phenyl, which is independently substituted with 0-2 R' subsituents;
(d) naphthyl, which is independently substituted with 0-2 R' subsituents;
and (e) a monocyclic or fused bicyclic heterocyclic ring system having from S to 10 ring atoms, wherein 1-4 ring atoms of the ring system are selected from N, O and S, and wherein the ring system may be substituted with 0-2 R' subsituents;
R' is selected from:
halo, C,~alkyl, -CN, (CHZ)mNR2R3, SOzNR2R3, SOZR2, CF3, ORZ, and a 5-6 membered aromatic heterocyclic system containing from 1-4 heteroatoms selected from N, O and S;
RZ and R3 are independently selected from the group consisting of H, C,~alkyl and Co~,alkylaryl, m is an integer of 0-2;
Y is a member selected from the group consisting of a direct link, -C(=O)-, -N(R4)-, -C(=O)-N(R4)-, -N(R4)-C(=O)-, -SOZ , -O-, S -SOz-N(R4)- and N(R4)-SOz-;
R4 is selected from:
H, C,~alkyl and C~alkylaryl;.
D is absent or is a member selected from the group consisting of (a) aryl, which is independently substituted with 0-2 R'a subsituents; and (b) a monocyclic or fused bicyclic heterocyclic ring system having from 5 to 10 ring atoms, wherein 1-4 ring atoms of the ring system are selected from N, O and S, -and wherein the ring system may be substituted with 0-2 R'a subsituents;
R'a is selected from:
Halo, C,~alkyl, -CN, -NOz, (CHz)mNRzaR3a, SOzNRzaR3a~ SOzRza~ CF3, ORza, and a 5-6 membered aromatic heterocyclic ring containing from 1-4 heteroatoms selected from N, O and S;
Rza and R3a are independently selected from the group consisting of H, C,~alkyl and C~alkylaryl;
E is a member selected from the group consisting of -N~S)-C(=O)-~ -C(=O)-N~5)-~ -N~5)-C(=O)-N~6)-~ -SOz-N~5)-~
-N(RS)-SOz N(R6)- and N(RS)-SOz-N(R6)-C(=O)-;
RS and R6 are independently selected from:
H, C,_4alkyl, Co~alkylaryl, C~alkylheteroaryl, C,~alkylCOOH and C,~alkylCOOC,~alkyl;
G is a member selected from the group consisting of:
a direct link, -CR'R8- and -CR'eRga-CR'aRBb-wherein R', R8, R'a, R$a, R'~ and Rgb are independently a member selected from from the group consisting of hydrogen, C,~alkyl, C~alkyl-C3_8cycloalkyl, C~alkylaryl, -OR9, -C°~alkylCOOR9, -C~,,alkylC(=O)NR9R'°, -N(R9)COR'°, -N(R9)C(=O)R'°, S -N(R9)SOZR'°, and common amino acid side chains;
R9 and R'° are independently selected from:
H, C,~alkyl and C°~alkylaryl;
J is a member selected from the group consisting of Rm I R"
U'2 ~n~ and wherein the ring carbons or the second ring nitrogen of the amino ring structure and/or the ring carbons on the alkylene bridging groups attached to the amino ring structure may be independently substituted by a total of 0 to 4 R", R"a, R"b and R"' groups;
R", R"a, R"b and R"' are independently a member selected from the group consisting of hydrogen, -OH, -O-C,~,alkyl, -C,~alkyl, CZ_6alkenyl, CZ_balkynyl, C3_ 8cycloalkyl, C°~alkyl-C3_8cycloalkyl, C°~alkylphenyl, C°~alkylnaphthyl, C°~alkylheterocyclic ring having from 1 to 4 hetero ring atoms selected from the group consisting of N, O and S, CHZCOOC,~alkyl, CHZCOOC,~alkylphenyl and CHzCOOC,~alkylnaphthyl;
Z is a member selected from the group consisting of:
(a) aryl, which is independently substituted with 0-2 R'b subsituents;and (b) a monocyclic or fused bicyclic heterocyclic ring system having from 5 to 10 ring atoms, wherein 1-4 ring atoms of the ring system are selected from N, O and S, and wherein the ring system may be substituted with 0-2 R'b subsituents;

R'b is selected from:
halo, C,~alkyl, -CN, -NO2, NRZbR3b' SOz~26R36' SOzR2b' CF3' OR2b' O-CH2 CHz-ORzb, O-CHz-COORzb, N(Rzb)-CHZ CHZ ORzb, N(-CHZ CHz-ORzb)z, N(Rzb)-C(=O)R36, N(Rzb)-SOz-R3b, and a 5-6 membered aromatic heterocyclic ring containing from 1-4 heteroatoms selected from N, O and S;
Rzb and R36 are independently selected from the group consisting of H, C,~alkyl and C~alkylaryl;
L is selected from:
H~ -CN~ C(-O)yzR~s~ (CHz)~~izR~3~ ~(-~12)~12R13' yzRis~ OR'z, _I~TR'zC(-NR'z)NR'zRi3 ~d NR'zC(=NR'z)-R~s;
R'z and R" are independently selected from:
hydrogen, -OR", -NR'4R's, C,~alkyl, C~alkylaryl COOC,~,alkyl, and COO-Co~alkylaryl;
R'4 and R's are independently selected from:
H and C,~alkyl; and and all pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives thereof.
In a further preferred embodiment, the present invention provides a compound according to the formula I:
A-Y-D-E-G-J-Z-L
wherein:
A is selected from:
(a) phenyl, which is independently substituted with 0-2 R' subsituents;
and (b) a monocyclic or fused bicyclic heterocyclic ring system having from 5 to 10 ring atoms, wherein 1-4 ring atoms of the ring system are selected from N, O and S, and wherein the ring system may be substituted with 0-2 R' subsituents;
R' is selected from:
halo, (CHz)",NRzR3, SOZNRZR' and SOZRZ;
RZ and R3 are independently selected from the group consisting of H and C,~alkyl;
Y is a member selected from the group consisting of a direct link, -C(=O)-, - SOZ- and -O-;
D is a member selected from the group consisting of (a) phenyl, which is independently substituted with 0-2 R'a subsituents;
and (b) a monocyclic or fused bicyclic heterocyclic ring system having from S to 10 ring atoms, wherein 1-4 ring atoms of the ring system are selected from N, O and S, and wherein the ring system may be substituted with 0-2 R'a subsituents;
R'a is selected from:
Halo and C,~alkyl;
RZa and R'a are independently selected from the group consisting of H, C,~alkyl, Co~alkylaryl;
E is a member selected from the group consisting of -N(RS)-C(=O)- and -C(=O)-N(RS)-;
RS and R6 are independently selected from:
H, C,~alkyl, C~alkylaryl and Co~alkylheteroaryl;
G is a member selected from the group consisting of a direct link, -CR'Rg- and -CR'aRBa-CR'aR86-wherein R', R8, R'a, Rga, R'~ and R86 are independently a member selected from from the group consisting of hydrogen, C,~alkyl, C°~alkyl-C3_8cycloalkyl, Co~alkylaryl, -OR9, -C°~alkylCOOR9, -C°~alkylC(=O) NR9R'°, -C~alkylC(=O)NR9-CHZ-CHz-O-S R'°, -Co-aalkYlC(=O)NR9(-CHZ-CHZ-O-R'°_)i, -N(R9)COR'°, -N(R9)C(=O)R'o, -N(R9)SOZR'°, and common amino acid side chains;
R9 and R'° are independently selected from:
H and C,~,alkyl, wherein the NR9R'° group of R', R8, R's, RBa, R'~ and R8b is optionally cyclized to form a 5-8 membered heterocyclic group;
J is a member selected from the group consisting of:
Ro I R"
~~~ 1_2 ~~ 1-2 and wherein the ring carbons or the second ring nitrogen of the amino ring structure may be substituted by a total of 0 to 2 R" and R"~ groups;
R", R"e, R"b and R"~ are independently a member selected from the group consisting of hydrogen, -OH, -O-C,~alkyl, -C,~alkyl, Cz_balkenyl, C~alkylaryl, and a C°~,alkylheterocyclic ring having from 1 to 4 hetero ring atoms selected from the group consisting of N, O and S;
Z is a member selected from the group consisting of (a) phenyl, which is independently substituted with 0-2 R'b subsituents;
(b) an aromatic heterocyclic ring having from 5 to 10 ring atoms, wherein 1-4 ring atoms are selected from N, O and S, and wherein the ring may be subsituted independently by from 0-2 R'b subsituents;
and (c) a fused aromatic bicyclic heterocyclic ring system having from S to ring atoms, wherein 1-4 ring atoms of the ring system are selected from N, O and S, wherein the bicyclic ring system may be substituted with 0-2 R'b subsituents;
5 R'b is selected from:
halo, C,.~alkyl, OH, OBn, O-CHz-CHz-OH, O-CHZ CHz OCH3, O-CHz COOH, O-CHZ C(=O)-O-CH3, NHz, NH-CHz-CHz-O-CH3, NH-C(=O)-O-CH3, and NH-SOz-CH3;
L is selected from:
10 H~ C(-O)yzRm~ (CHz)n~tzRt3 ~d C(=NR'z)NR'zR~3~
R'z and R'3 are independently selected from:
hydrogen and C,~alkyl;
and all pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives thereof.
In a further preferred embodiment, the present invention provides a compound according to formula I:
A-D-E-G-J-Z-L
wherein A is a member selected from the group consisting of OZNHz 02NHMe OZNHBu(t) OZMe HZNHz HZNMez D is a member selected from the group consisting of / \ /- / \ / \
F
F F F
/ \ / \ / \
F a F
S E is a member selected from the group consisting of::
-C(=O)-NH-, -C(=O)-N(-CH,)-, C(=O)-N(-Bn)-, -NH-C(=O)-, -N(-CH3)-C(=O)- and -N(-Bn)C(=O)-;
G is a member selected from the group consisting of a direct link, -CH-(-NHZ)-CHz , -CH-(-NH(C(=O)-CH3))-CHz-, -CH-(-NH(C(=O)-Ph))-CHZ , -CH-(C(=O)-OR8)-, -CH(-R')-, -CHZ-CH(C(=O)-OR8)-, and -CHZ CH(C(=O)-N(-R8, -R8))-;
R' is a member selected from the group consisting of H, phenyl, Bn, -O-loweralkyl and cycohexyl;
R$ is a member selected from the group consisting of H, C,_6alkyl, -O-loweralkyl and C3_bcycloalkyl;
J is a member selected from the group consisting of R1 t c ~~ 1_2 ~~ 1_2 r.~ and wherein the second ring nitrogen of the amino ring structure may be substituted by a R"~ group;
R"~ is a member selected from the group consisting of H, methyl, phenyl and benzyl; and Z and L taken together are a member selected from the group consisting of:
OCHZCOOH OH F OMe OCHzCH20H OCI-hCHZOMe \ \
I/ I/ I/ I/ I/ I/ I/
Hz NH Hz NH Hz NH Hz NH Hz NH Hz NH Hz NH
CHzCOOMe NHCH1COOH N(CHzCH20Mey~ NH(CHZCCHZOMe) \ \
I \ I / I / I / ~ / F I / OH
Hz NH Hz NH
Hz NH Hz NH Hz NH Hz NH
\ \ \ \ F
\ \ \ I I I I
/ NH /~O /~S /
I / I / I \
N~ ~ -N -N -N
Hz O HZN HzN HZN HzN Hz NH
OH N~ OH NHz \ \
/ \ I / I / I / g I / NH
\ ~~H O
N~ I / N/ N ~NHz ~Nf'~z Hz 'O N~ HzN HZN
and all pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives thereof.
The following non-limiting tables illustrate representative compounds of the present invention:

Table 1 Ib'~
R~~, R ~~ R~h~
R
H H H H
Me Me H OH
I F H

~:
OH
Table la OyNHy ... ...
H
1b' Form R», R~r Rio. Rye.
H H H H
Me Me H OH
\ \
I / I ~ F H
I / I ~ -OH F
H~
H
r mma a Table 1b OpNHp H
1b' Formula Rtr Rtt' Rtb, Rtb-H H H H
Me Me H OH
F H
-OH F
CH=
OH
Table lc Rttc Rtt O pNH p N
Rtb.
N ~N
~ H
Rtb' Formula IIc HN NHy Rtt Rttc Rtt~ Rtb' H H H H
Me Me H OH
Me F H
Me ~ / -OH F
OH

Table 1d OpNH2 H
Formula 1b' Rtt, Rtt. Rte, Rtb.
H H H H
Me Me H OH
Me F H
Me I / -OH F
OH
Table 1 a Rttc Rtt OzNHz N Rt°~
N
H I' /~
V 'otb' Formula IIe Rtt Rtic Rtb~ Rtb' H H H H
Me Me H OH
F H
-OH F
CHz OH

Table 2 OpNH2 Rtt' Rtu N
H Rtr NH
HpN
Formula III
Rtt' Rtt' Rtn H H H
Me Me H
\ \
/ F
\
-OH
CHi OH
Table 2a Rtr Rtt.
OyNH2 Rto N ~~~\~ ~~ \
H
[JH
Formula IIIa HZN NN
R ~ R ~ Rto H H H

Me Me H

Me F

Me ~ / -OH
OH

Table 2b H H H
Me ~ Me H
\ \
F
-OH
CHZ
OH
Table 2c OZNHZ ,b N ~~
H
NH
Formula IIIc HZN N
R »' R"c R , b H H H
Me Me H
\ Me F
Me ~ / -OH
OH
Formula IIIb Table 2d R~~
R~~~
OzNHz HN Rib N- ''-N
H ~ , ~H
Formula llld HzN NN
Rw Rir Rib H H H
Me Me H
Me F
Me / -O H
OH
Table 2e H
F~rmu R»' Rttc R7u H H H
Me Me H
\ F
/ ~ /
\
-OH
CHZ
OH

Table 3 OzNHz Rtr Rip N
H
R" /
HzN N
Formula IV
Rti' R»~ Rin H H H
Me Me H
\ I \ F
I \
-OH
CH=
OH
Table 3a OzNH2 H
Form R »~ Rat H H H
Me ~ Me H
F
-OH
CHz OH

Table 3b R "' O zNH z Rib H N
R~~~ /
Formula IVb HZN N
R ~~ R ~ R

H H H

Me Me H

F

I \
-OH

CHZ
OH

Table 3c OpNH2 H
For R»' R»c Rtb H H H
Me Me H
\ \
F
-OH

OH

Table 3d OzNHp H
Formula m a Rtt Rttc Rtb H H H
Me Me H
\ F
/ ~ /
\
-OH
CHz OH
Table 3e Rttc Rtt OZNH2 ~~ Rto H N
Formula IVe HZN ~N
Rtt Rttc Rtb H H H

Me Me H

\ \
F

-OH

CHZ
OH

Table 4 O2NHZ R~r Rib N
H R », Formula V HZN N
R , R . R

H H H

Me Me H

F
/ ~ /

-OH
CHy H

Table 4a OpNHz H
Formula R», R . Rtb H H H
Me Me H
\ \
/ F
-OH
CHz OH

Table 4b OZNHp H
Formula .., _R~r H H H
Me Me H
/ F
-OH
CHZ
OH
Table 4c Rttc R»
OzNHZ
N' V-N \
H
Formula VC HZN N
R» R»c RW
H H H
Me Me H
F
-OH
CH=
OH

Table 4d R"
I
O pNH p N R,o R~~
N
Formula Vd HzN
R" R"c R,o H H H
Me Me H
\ \
I / I F
-OH
CHZ
OH
Table 4e ~,lc R"
OzNHz R,t H N
Formula Ve HzN 1 Rtt R"c R1b -H H H
Me Me H
\ \
F
\
-OH
CH=
OH

Table 5 OpNHz Rtt' Rtb H Rtt I N
Formula VI HZN N
Rtt' Rtt ~ Rtb H H H
Me Me H
\ \
I / I / F
I I / -OH
CHz OH
Table Sa OzNH2 Formul, R», R _ R
H H H
Me ~ Me H
F
/ -OH
CHz OH

Table Sb R~~
OpNHy R1b N
H Rt1' Formula VIb R~~, R». Rtb H H H
Me Me H
\ \
F
\
-OH
CHZ
OH
Table Sc OpNH2 H
Formula R» RW Rib H H H
Me Me H
\ \
F
I \
-OH
CHZ
OH

Table Sd OzNHp H
Forr R11 Rllc R1b H H H

Me Me H

\ F
/ ~ /

-OH
CHZ
H

Table Se R~lc OzNH2 N
N
H
Formula ' VIe HzN I N
Rt~c H H H
Me Me H
\ \
F
-OH
CHZ
OH

Table 6 OpNH2 R»" Rtb N
H
R~~
Formula VII
N
R»' Rw RW
H H H
Me Me H
F
/ ~ /
-OH
CHZ
OH
Table 6a OzNH2 H
FOrml R»' Rto Rat H H H
Me ~ Me H
\ \
F
I \
/ ~ -OH
CHz OH

Table 6b OpNHZ
Formula R»' R~r Rat H H H
Me Me H
\ I\ F
I/
I\
-OH
I
CHZ
OH
Table 6c OpNHy H
Four R11 Rllc Rlb..

H H H

Me Me H

\ \
I / F

I / I ~ -off CHZ
OH

Table 6d R11 Rl~c Rib H H H
Me Me H
\ I \ F
I \
-OH
CHZ
OH
Table 6e OpNHp H
Forma Rllc R1b H H H
Me Me H
\ \
F
I \
-OH
CH=
OH

Table 7 A D A D
OZNHz HZN Mez F
CI
OpNHMe F
OzNHf3u(t) CI
OZMe F
F
HzNH F
HZ I
N
F
HZNHMe Hz N/
F
".~a~~.~ ...~ H2 Table 7a !H2 A D A D
OZN Hz HZN Mez F
CI
OzNHMe F
OZNHBu(t) N/ \
CI
O2Me F
F
HZNHz F
N N
Hz i ~ I-~
F
HZNHMe H
z F

Table 7c A D A D
OZNHp HZNMe2 F
CI
OZNHMe F
OZNHBu(t) CI
OZMe F
F
HZNH F
Hz I
F
HZNHMe HZ
F

Table 7c A D A D
OzNHz HZNMe2 F
CI
OZNHMe /
F
O2NHBu(t) /
CI
OZMe F
F
HpNHz F
HZ
F
HzNHMe H2 / ~ / \ N~
F N

Table 7d A D A D
OzNH2 HZNMe2 F
CI
OpNHMe /
F
OZNHBu(t) /
CI
OzMe F
F
HpNH F
HZ /
N
F
HZNHMe / ~ Hz / \
I ~ ~ ~N
F
Formula VIBd H2 Table 7e A D A D
OZNHz HZNMez F
CI
OZNHMe F
OZNHBu(t) CI
OZMe F
F
HZNHz F
Hz I
F
HZNHMe Hz F

Table 8 H
Formula IX
A D A D
OZNHz HZN Mey F
CI
OzNHMe F
02NHt3u(t) CI
OZMe F
F
HZNHZ F
HZ ~
F
HpNHMe H2 F
wherein R'b is a member selected from the group consisting of H, F, -OH, Br, Cl, -NH2, -O-CHZ-O-Ph and -O-CHz-CHZ-O-CH,, Table 8a H
Formula IXa A D A D
02NHz HZNMez F
CI
OpNHMe F
OZNHt3u(t) CI
OZMe F
F
HZNHz F
Hz ~
F
HzNHMe H
z N
F
wherein R'b is a member selected from the group consisting of H, F, -OH, -SO-Br, Cl, -NHz, -O-CHz-O-Ph and -O-CHZ-CHz-O-CH3, Table 8b OZNH2 ., Formula IXb A D A D
OzNH2 HZN Mez F
CI
OzNHMe F
OZNHBu(t) CI
02Me F
F
HzNHZ F
Hz ~
N
F
HZNHMe Hz F
wherein R'b is a member selected from the group consisting of H, F, -OH, Br, Cl, -NH2, -O-CHZ-O-Ph and -O-CHZ-CHZ-O-CH3, Table 8c H
Formula IXc A D A D
OpN Hy HZN Mey F
CI
OzNHMe F
OzNHBu(t) CI
OZMe F
F
HZNH F
HZ
F
HZNHMe Hz F
wherein R'b is a member selected from the group consisting of H, F, -OH, Br, Cl, -NH2, -O-CHZ-O-Ph and -O-CHz-CHZ-O-CH3, Table 8d H
A D A D
OZNHZ HZNMep F
CI
OZNHMe F
OzNHBu(t) CI
OZMe F
F
HzNH2 F
I ~ ~ ~ HZ I
F
HZNHMe H:
F
wherein R'b is a member selected from the group consisting of H, F, -OH, Br, Cl, -NHZ, -O-CHz-O-Ph and -O-CHZ-CHZ-O-CH3, Table 8e OzNHz ~A~ ~D~
H
Formula IXe A D A D
OZN HZ HZN Me2 F
CI
OZNHMe F
OzNHl3u(t) CI
OzMe F
F
HyNH2 F
Hz F
HZNHMe H2 N/ ~ N
F
wherein R'b is a member selected from the group consisting of H, F, -OH, Br, Cl, -NHz, -O-CHz-O-Ph and -O-CHZ-CHZ-O-CH3, Table 9 A D A D
OZNHz HZN Me2 F
CI
O2NHMe F
OZNHBu(t) CI
OZMe F
F
HZNHz F
N N
HZ I
F
HZNHMe Hz F
Formula X

Table 9a A D A D
OZNHz HZNMez F
CI
OZNHMe F
OzNHBu(t) CI
OzMe F
F
HzNHz F
Hz N
F
HZNHMe Hz F

Table 9b Formula Xb A D A D
OZNHZ HZNMez F
CI
OzNHMe F
OZNHBu(t) CI
OZMe F
F
HzNHz F
Hz ~
F
HpNHMe H2 N
F

Table 9c f Formt A D A D
OzNH2 HZNMez F
CI
OpNHMe F
OZNHt3u(t) CI
OZMe F
F
HzNH2 F
Hz F
HZNHMe ~ ~ Hz N
N
F

Table 9d A D A D
OZNHz HZNMe2 F
CI
OZNHMe F
OZNHBu(t) CI
OZMe F
F
HzNH2 F
HZ ~
F
HZNHMe Ha F

Table 9e OzNH2 Fore A D A D
OZNH2 HZNMep F
CI
OyNHMe F
OyNHBu(t) CI
OzMe F
F
HpNH2 F
N N
HZ I ~ I-~
F
HZNHMe Hs F

Table 10 OZNHZ
Formul A D A D
OzN HZ HZN Mez F
CI
OzNHMe F
OZNHBu(t) CI
OzMe F
F
HZNHz F
N N
HZ ~
F
HZNHMe H2 N
F

Table 10a A D A D
OyNHz H2NMez F
CI
OZNHMe F
OzNHBu(Q
CI
OzMe F
F
HZNHz F
N N
Hz F
HyNHMe Hz F

Table lOb A D A D
OyNHp HzNMep F
CI
O=NHMe F
OZNHBu(t) CI
OZMe F
F
HZNH F
HZ
F
HZNHMe H2 N
F
rormuia ~m Table lOc H
N
A D A D
OyN Hz HZN Mez F
CI
OpNHMe F
OZNHBu(t) CI
OyMe F
F
~NHz F
Hz I
F
HzNHMe Hz F

Table lOd OzNHz H
Formula A D A D
OzNH2 HZNMe2 F
CI
OzNHMe F
OzNHBu(t) CI ' OzMe F
F
HyNHy F
HZ
F
HzNHMe Hz F

Table 10e A D A D
OZN Hp H=N Mez F
CI
OZNHMe F
OZNHBu(t) CI
OzMe F
F
HZNHz F
Hz ~ ~ ~-~' F
HZNHMe Hz N
F

Table 11 a o a o OZNHz HZNMe2 F
CI
OZNHMe F
OZNHBU(t) N
CI
OpMe F
F
FiiNHp F
N N
HZ
F
HZNHMe Hs I ~ / \ N~
F

Table 11 a A D A D
OZNHz HZNMez F
CI
OZNHMe F
OzNHt3u(t) CI
OpMe F
F
F
HZNHz N N
HZ
F
HZNHMe Hs N
F

Table 11 b A D A D
OZNHz HzNMez F
CI
OyNHMe F
OZNHBu(t) CI
OZMe F
F
HZNHz F
Hz F
HZNHMe Hz F

Table 11 c A D A D
OzNHZ H2N Mez F
CI
OzNHMe F
OZNHBu(t) CI
02Me F
F
HZNHp F
N N
HZ I
F
H2NHMe HZ
F N

Table 11 d OzNHz Formula A D A D
OZNHp HZN MeZ F
CI
OZNHMe F
OzNHBu(t) CI
OzMe F
F
HZNH F
N N
HZ
F
H NHMe HZ N
N
F

Table 11 a OzNH2 \A/ \D/ NH
Formula X
A D A D
OZN HZ HzN Mez F
CI
OZNHMe F
OZNHBu(t) CI
OZMe F
F
HyNH2 F
HZ
N
F
HZNHMe H2 F

Table 12 )H
OzNHz H
Formula XIII
A D A D
OZN H2 HzN Me2 F
CI
OzNHMe F
OZNHBu(t) CI
OpMe F
F
HpNH2 F
HZ
F
HyNHMe ~ ~ HZ
F

Table 12a A D A D
OZNHz HZN Me2 F
CI
OzNHMe F
OzNHBu(t) CI
OZMe F
F
I-hNH F
HZ I
N
F
HZNHMe H2 F

Table 12b OpNHz Formula XIII
A D A D
OZNHZ HZN Me2 F
CI
02NHMe F
OZNHt3u(t) CI
OzMe F
F
HzNHz F
N N
Hz I
F
HzNHMe ~ ~ Hz N
F

Table 12c OzNH2 \A~ \p~ NH
Formula A D A D
OZNHz HZN Mez F
CI
OZNHMe F
OZNHBu(t) CI
OZMe F
F
HzNHz F
Hz ~
N
F
HyNHMe Hz F

Table 12d A D A D
OzNHz HZNMez F
CI
OzNHMe F
OZNHBu(t) CI
OZMe F
F
~NHz F
Hz ~
F
HZNHMe Hz F

_77_ Table 12e A D A D
OzNHZ HZNMez F
CI
OZNHMe F
OZNHBu(t) CI
OZMe F
F
HZNHZ F
HZ ~
F
HZNHMe ~ ~ Hs N
F

_78_ Table 13 Formula XN
A D A D
O2NHz HZNMeZ F
/ \ / \ / \ / \
C
OzNHMe / \ / \ / \ / \
F
OzNHl3u(t) / \ / \ / \ / \
ci OpMe F
/ \ / \ / \ /-\
F
HzNH2 F
/ \ / \ NhZ / \ / \
F
HZN H Me H2 / \ / ~ / \
F

Table 13a Formula XIVa A D A D
OZNHZ HZNMe2 F
/ \ / \ / \ / \
C
OyN H Me / \ / \ / \ / \
F
OZNHBu(t) / \ / \ / \ / \
CI
OzMe F
/ \ / \ / \ / \
F
HZNHZ F
/ \ / \ Nnz / \ / \
F
HZNHMe HZ
/ \ / \ / \
F

Table 13b Formula XIVb A D A D
02NHz HZNMe2 F
/ \ / \ / \ / \
C
OZNHMe / \ / \ / \ / \
F
OZNHBu(t) / \ / \ / \
/ \
CI
OZMe F
/ \ / \ / \ /-\
F
HzNHy F
/ \ / ~ Nh2 / \
F
HZNH Me H2 / \ / ~ / \
F

Table 13c Formula XIVc A D A D
OZNHZ HZNMeZ F
C
O2N H Me F
OzNHBu(t) CI
OZMe F
F ' HzNH F
Nhy /
F
H NHMe F

Table 14 Formula XV
A D A D
OzNHp HzNMez F
/ \ / \ / \ / \
C
OZNHMe / \ / \ / \ / \
F
OZNHt3u(t) / \ / \ / \
/ \
CI
OZMe F
/ \ / \ / \ /-\
F
HzNH F
/ \ / \ Nhz / \ /-\
F
HzNHMe / \ / \ / \
F

Table 14a Formula XVa A D A D
OzNHz HZNMez F
/ \ / \ / \ / \
CI
OZNHMe / \ / \ / \ / \
F
OzNHBu(t) / \ / \ / \
/ \
CI
OZMe F
/ \ / \ / \ /-\
F
HzNHz F
/ \ / \ NhZ / \ / \
F
HzNHMe Hz / \ / ~ / \
F

Table 14b Formula XVb A D A D
OZNHZ HZNMez F
/ \ / \ / \ / \
CI
OzN H Me / \ / \ / \ / \
F
OZNHBu(t) / \ / \ / \ / \
CI
OZMe F
/ \ / \ / \ / \
F
I-hNH2 F
/ \ / \ Nh2 / \ / \
F
HZNHMe Hz / \ / ~ / \
F

Table 14c Formula XVc A D A D
02N HZ HZN Mey F
/ \ / \ / \ / \
C
OZNHMe / \ / ~ / \ / \
F
OZNHBu(t) / \ / \ / \
/ \
ci OZMe F
/ \ / \ / \
F
HZNHz F
/ \ / \ Nh2 / \ /-\
F
HzNHMe Hz / \ / ~ / \
F

Table 15 A D A D
OZNHZ H2NMez F
/ \ / \ / \ / \
CI
OyNHMe / \ / \ / \ / \
F
OpNHBu(t) / \ / \ / \
/ \
CI
OzMe F
/ \ / \ / \
F
HZNHZ F
/ \ / \ Nh2 / \
F
HZNHMe Hz / \ / \ / \
F
Formula XVI

_87_ Table 15a !H2 Formula XVIa A D A D
OzNHZ HzNMe2 F
/ ~ /
C
OyNHMe / ~ /
F
OZNHBu(t) / ~ /
CI
OZMe F
/ ~ / \ / ~ / \
F
HzNH F
/ ~ / ~ Nnz / ~ / \
F
H2N H Me H2 / ~ /
F N

_8g_ Table 1 Sb dH2 Formula XVIb A D A D
OZNHZ HzNMe2 F
C
SOZNHMe F
OZNHBu(t) CI
OZMe F
F
HpNH F
Nh2 /
F
HzNHMe /
F

Table 1 Sc OH
Formula XVIc A D A D
OzNHz HpNMez F
/ ~ /
C
O2NHMe / ~ /
F
OzNHBu(t) /
/
CI
OZMe F
/ ~ /
F
HZNHz F
/ ~ / ~ Nnz / ~ / \
F
HZNHMe H2 /
F

Table 16 Formula XVII
A D A D
OzNH2 HzNMez F
/ ~ /
G
OzNHMe / ~ /
F
OZNHBu(t) / ~ /
G
O=Me F
% ~ /-\
F
HpNHy F
Nhz / ~ /-\
F
zNHMe Hz F/ ~ /
N

Table 16a Formula XVIIa A D A D
OZNHz HZNMe2 F
/ \ / \ / \ / \
C
OzNHMe / \ / \ / \ / \
F
OzNHl3u(t) / \ / \ / \ / \
CI
OzMe F
/ \ / \ / \ /-\
F
HZNHZ F
/ \ / \ Nhz / \ /-\
F
HzNH Me H2 / \ / ~ / \
F

Table 16b Formula XVIIb A D A D
OZNHz HzNMez F
/ \ / \ / \ / \
C
OZN HMe / \ / \ / \ / \
F
OZNHBu(t) / \ / \ / \ / \
CI
OZMe F
/ \ / \ / \ /-\
F
HzNH F
/ \ / \ Nhz / \ /-\
F
H2NHMe Hz / \ / ~ / \
F

Table 16c A D A D
OZNHz HZNMez F
C
OZNHMe F
O2NHt3u(t) /
CI
OZMe F
-\
F
HzNHz F
Nhz / ~ ~ \
F
HzNHMe Hz /
F
Formula XVIIc Table 17 1 b"
R7 ~ R11 ~ R1b' Rib"
H H H H
Me H H OH
\ F H
/ -OH F
CHz OH
OH
\
/ OH OH
CHZ
H _ OMe I \ / -NH2 H
/ CHz Formula XVIII

Table 17a Formula XVBIa R7 ~ R11 ~ R1b' ~ R1b"
H H H H
Me H H OH
\ F H
(/ ~/
/ -OH F
CHz OH
OH
/ OH OH
CHZ
Hz- OMe \
\ / -NH2 H
/ CHz Table 17b 1b"
R7 ~ R11 ~ R1b' ~ R1b"
H H H H
Me H H OH
\ \
F H
/ -OH F
CHz OH
OH
\
/ OH OH
CHZ
H_ OMe z \
I \ / -NH2 H
/ CHz Formula XVIIIb _97_ Table 17c R7 ~ R11 ~ R1b' ~ R1b~

H H H H

Me H H OH

\ \
F H

/ -OH F

CHZ
OH

OH
/ OH OH

CHZ

H OMe \ / -NH2 H

I CHz /

Formula XVIIIc Table 18 \ \
H H I/ I/
H=
H
OH
Me H I /
H=
Hi. \ OMe I\ I/ I\ I/
/
H~
Table 18a I

NH
/
NHS
Formula XIXa - R7 Rltc R7 Rllc \ \
" H I I/

CH=
OH

H
Me H I /

CH=

H=. \ OMe \ / \ /
/ /

CHi t' ormula XIX ' Table 18b R"

N ~ \ ~ /NH
H
R~
Formula XIXb R~ R~ ~ R~ R~ ~
\ \
H H I / I /
CHy OH
H
Me H I /

HZ_ \ OMe I ~ I / I ~ /
CHZ

Table 18c R"°
02NHz N ~ ~ ~ NH
H /
R~
Formula XIXc NH2 R7 R "c R7 R "c w H H I / I /
CHZ
OH
H
Me H I /
CHz HZ_ OMe \ / I \ /
/ / CHZ
1~

Table 19 OZNH2 R~~
H I,, Formula XX
R~ R~~ R7 R~~
H H I / I /
CHZ
OH
H
Me H ( /
CHZ
H=_ OMe I\ I/ I\ I/
/ / CHz Table 19a Rl~c 'I
N N
~ H
R~

Formula XXa R7 R~~c R~ Rllc H H I / I /
CHx OH
H
Me H I /
CH=
Hz_ \ OMe I\ / I\ I/
/ / CHz Table 19b R~~
OpNHz ~ \
N~ \ I / N
H ~I,,, ~z Formula XXb R~ R~~ R~ R~~
\
H H I / I /
CHZ
OH
H
Me H I /
CHZ
HZ_ OMe I\ I/ I\ /
/ /
H=
Table 19c Rllc OZNHz N
N ~ ~ I
H
R
NHz Formula XXc R7 R~tc R7 R~lc H H I I /

/ CHZ
OH

H
Me H I /

CHZ

Hx_ Me I\ / I\ /
/ /

CH=

Table 20 OZNHz Rtt N
R~
Formula XXI H2N
R~ Rtt R~ Rtt \ \
H H I I /

/ CHZ
OH

H
Me H I /

CHz HZ_ \ OMe I\ I/ I\ I/
/ /

CHz Table 21 OZNHp Rtt N iH
H ~ ~ ~ ~N
R
HzN
Formula XXII
R~ Rtt R~ Rtt H H I I /

/ CH=
OH

H
Me H I /

CH=

Hz_ \ OMa I\ I/ I\ I/
/ /

CHZ

Table 20a R "~
OZNHz I
/ O~
N
\ / \ / H
R~
NHy Formula XXIa R7 R"c R7 R,tc \
H H I I /

/ CHI
OH

H
Me H I /

CHZ

Hx_ \ Me I \ I / I \ I /
/ /

CHz Table 21a R "c / N\
\ / \ / H
R~
NHZ
Formula XXIIa R7 R"c R7 R"c H H I I /

/ CH=
OH

H
Me H I /

CH=

Hz_ \ a I\ I/ I\ I/

CHZ

Table 20b OzNH2 Rtt H
R~
Formula XXIb HZN
R~ Rtt R~ Rtt H H I I /

OH

H
,",e H I /

CH=

Hz. \ Me I\ I/ I\ I/
/ /

CHZ

Table 21b H
OzNHz Rtt ~ / N\
N \ I /N
H NHZ
Formula XXIIb R~ Rtt R~ Rtt H
H I I/

/ CHI
OH

H
Me H I /

CHZ

HZ_ \ OMe I\ I/ I\ I/
/ /

CHz Table 20c "_ OZNHZ
H
Formula R 7 R"c R 7 R"c \
H H I I /

/ CHZ
OH

H
Me H I /

CHZ

Hs_ \ OMe \ I/ I\ I/
/ /

CHy Table 21c R"~
OzNHy N H
N~
N
H N \
R~ NH2 Formula XXIIc R7 R"c R7 R"c \ \
H H I I /

/ CHy OH

H
Me H I /

CHZ

Hz_ \ OMe I\ I/ I\ I/
/ /

CHz Table 22 OzNHz H
Form R~ R~~ R~ R~~

\
H H I I /

/ CHz OH

H
Me H ~ /

CHz Hz_ \ OMe / ~ /

CHz Table 23 OpNHp R~~
H ~ ~H
R ~ ~ NiN
Formula XXIV
R~ R~~ R~ R~~
\
H H I / I /
CHz OH
H
Me H I /
CHz H=_ \ OMe I\ / I\ I/
/ /
~z Table 22a Formu R7 Rt~c R7 R~lc H H I I /

/ CHx OH

H
Me H I /

CHx Hx_ \ OMe I\ I/ I\ /
/ /

CHx Table 23 a R~~°

H ~ ~ ~ iH
R Ni N
Formula XXIVa R~ R~~ R7 R11 c \
H H I I /

/ CHx OH

H
Me H I /

CHx Hx_ \ OMe I/ I/ I/ I/

CHx Table 22b OzNH2 R~~
R~
/ N
HZN
Formula XXIIIb R~ Rat R~ R~~

\ \
H H I I/

CHx OH

H
H I/

CHI

Hz_ \ OMe \ / \ I/
/ /

CHz Table 23b OZNHp O
R~~
iH
NON
Formula XXIVb R~ R~~ R~ R~~

H H I I /

/ CHz OH

H
Me H I /

CHx Hz_ \ OMe \ / I\ I/
/ /

~z Table 22c O yN Hz H
Formula R7 Rttc R7 Rttc H H I I /

/ CHx OH

H
Me H I /

CHp H=_ OMe I\ / I\ I/
/ /

CHp Table 23c R7 Rttc R7 Rttc H H I / I /
CHi OH
H
Me H I /
CHZ
HZ_ OMe I\ I/ I\ I/
/ /
MHz Formula XXIVc Table 24 R~~
OZNHz H R~
N NHz Formula XXV
R~ R~~ R7 R~~

\
H H I I /

/ CHz OH

H
Me H I /

CHZ

HZ. \ OMe I\ I/ I\ I/
/ /

CHZ

Table 24a R~~
OpNHp N
H
R~

Formula XXVa R~ R~~ R~ Rllc H H I I /

/ CHx OH

H
Me H I /

CHz I \ I / I \_ I % Me / /

CHi Table 24b 02NHz H

Formula XXVb \
H H I I /

/ CHz OH

H
Me H I /

CHz HZ_ Me / I/ I\ I/
/

CHx Table 24c .._ H
NHp Formula XXVc R7 R~lc R7 Rllc \
H H I
I/

OH

H
Me H I

CHx Hz_ \ OMe \ I/ I\ I/
/ /

CHz Table 29c Rtt° Rtt OzNH2 _ N~~ H
N
H N I ~NH2 N
Formula XXXc Rtt Rtt~ Rtt Rtt \
H H I I /

/ CHp OH

H
Me H I /

CHZ

H=_ \ OMe \ / \ /
/ /

CHZ

Table 26 R"~ R"' OZNHz H ~ ~ NI
HpN
Formula XXVI
Rtt, Rtt. Rtt, Rtt.
\
H H I / I /
CH=
OH
H
Me H I /

H2. \ OMe I\ I/ I\ I/
/ /
CHz Table 25a Rtt° Rtt OzNH2 I
- / O~
~ H \ I ~N
Formula XXVIa NHZ
Rtt Rtt~ Rtt Rtt w H H I I /

/ CHZ
OH

H
Me H I /

CH=

HZ_ Me \ I
/ I\ /
/ /

CHI

Table 26a 02NHz Rtt~ Rtt I H
/ N~
\
Formula XXVIIa NHz Rtt Rtt ~ Rtt Rtt H H I / I /
H CHz H
\ _ Me H I /
HZ
H=_ \ OMe I\ I/ I\ I/
/ / H=

Table 25b OZNHZ Rtt' tt' I
O~
H N
NHz Formula XXVIb Rtt, Rtt. Rtt, Rtt.

\
H H I I /

/ CHx OH

H
Me H ( /

CHZ

Hz_ \ Me \ / \ /
/ /

CHz Table 26b OZNHZ Rtt. Rtt.
H
N~
H N \ I /N
Formula XXVIIb NHZ
Rtt, Rtt. Rtt, Rtt.

w \
H H I I /

/ CHI
OH

H
Me H I /

CHz Hz. \ OMe \ / \ /
/ /

CHz Table 25c O2NH2 Rttc Rtt N~
H N ~ I
Formula XXVIc H2N
Rtt Rttc Rtt Rttc \
H H I I /

/ CHz OH

H
Me H I /

CHZ

HZ_ \ OMe \ I/ I\ I/
/ /

CHZ

Table 26c O NH Rttc Rtt N H
N
~ H N ~
Formula XXVIIc NH2 Rtt Rttc Rtt Rttc \
H H I / I /
CHz OH
H
Me H I
CH=
HZ_ \ OMe I\ I/ I\ I/
/ CHZ

Table 27 OZNHZ
H
Formula ~~ v m Rat. R. R, Rm.

\
H H I I /

/ CHz OH

H
Me H I /

CHx H z_ Me \ I/ I\ I/
/ /

CHz Table 28 OpNH2 R~~ R11 H ~ ~ NH
NON
Formula XXIX
Rat, R~~. Rte, R~~.

H H I I/

/ CHx OH

H
Me H I /

CHx Hz_ OMe \ / I\ /
/ /

CHx Table 27a 02NH2 R~~' R~~
I
S
H

Formula XXVIIIa R'I'I Rllc R1~ R11 c H H I I /

/ CHz OH

H
Me H I /

CHz Hz_ OMe I\ I/ I\ /
/ /

CHz Table 28a 02NHz R~~° R~~
_ _ I H
V N
H I //N
N ~ N
Formula XXIXa R11 Rllc R11 R1'Ic \ \
H H I I /

/ CHz OH

H
Me H I /

CHz Hz_ \ OMe \ I/ I\ I/
/ /

CHz Table 27b OpNH2 Rtr Rtr S~
w w H O y , NHZ
Formula XXVIIIb Rtt, Rtt. Rtt, Rtt.

~ \
H H I I /

/ CHZ
OH

H
Me H I /

Hz_ \ OMe \ / I\ /
/ /

CHZ

Table 28b OpNHp Rtt~ Rtt' H
N
ii ~N
Formula XXIXb Rtt. Rtr Rtt. Rtr H H I I /

OH

H
Me H I /

CHZ

HZ_ \ OMe \ I/ I\ /
/ /

CHZ

Table 27c Rttc Rtt 02NHp S\
H N

Formula XXVIIIc Rtt Rttc Rtt Rttc H H I I /

/ CHx OH

H
Me H I /

CHx Hx_ \ a I\ / I\ /
/ /

CHx Table 28c OpNHp Rttc Rtt N ~~ H
/ N\
H N
N
Formula XXIXc Rtt Rttc Rtt Rttc \ \
H H I I /

/ CHx OH

H
Me H I /

CHx H x. OMe I\ / I\ /
/ /

CHx Table 29 R~~~ R~~
02NHz N
H
N NHz Formula XXX
R~~~ R~~~ R~~~ R~~

\ \
H H I I /

/ CHy OH

H
Me H I /

CHZ

Hz_ \ OMe I\ I/ I\ I/
/ /

CHZ

Table 29a OpNHp Roc R~r N N
H N \ I ~NH2 'N
Formula XXXa Rtt~ Rllc Rtl~ Rltc H H I I /

/ CHz OH

H
Me H I /

CHZ

H z. Me I\ I/ I\ I/
/ /

Table 29b OZNHp Rtr Rtr H
N
-N H z 'N
Formula XXXb Rtt, R. Rtt, Rtt.

\ \
H H I I /

/ CHI
OH

H
Me H I /

CHp Hx_ \ OMe \ / \ I/
/ /

CHZ

Table 29c Rttc Rtt 02NHp _ / N
N ~ ~NH2 N
Formula XXXc Rtt Ritc Rtt Rttc H H I I /

/ CHp OH

H
Me H I /

CHZ

H~_ \ OMe \ / \ /
/ /

CHz Also preferred are compounds according to Tables 1 through Table 24c, wherein the following groups:

/ ~ / ~ and ~A/ gyp/

when they occur in each of the formulae of the Tables are exchanged for a group having the carboxamide group in a reverse horizontal orientation as follows:

/ ~ / I- and ~ A/ ~ p / I-wherein the RS substituent is the hydrogen or other amino substituent shown in the respective Tables 1 through 24c.
This invention also encompasses all pharmaceutically acceptable isomers, salts, hydrates and solvates of the compounds of formulas I, II and III. In addition, the compounds of formulas I, II and III can exist in various isomeric and tautomeric forms, and all such forms are meant to be included in the invention, along with pharmaceutically acceptable salts, hydrates and solvates of such isomers and tautomers.
The compounds of this invention may be isolated as the free acid or base or converted to salts of various inorganic and organic acids and bases. Such salts are within the scope of this invention. Non-toxic and physiologically compatible salts are particularly useful although other less desirable salts may have use in the processes of isolation and purification.
A number of methods are useful for the preparation of the salts described above and are known to those skilled in the art. For example, the free acid or free base form of a compound of one of the formulas above can be reacted with one or more molar equivalents of the desired acid or base in a solvent or solvent mixture in which the salt is insoluble, or in a solvent like water after which the solvent is removed by evaporation, distillation or freeze drying. Alternatively, the free acid or base form of the product may be passed over an ion exchange resin to form the S desired salt or one salt form of the product may be converted to another using the same general process.
Prodrug Derivatives of Compounds This invention also encompasses prodrug derivatives of the compounds contained herein. The term "prodrug" refers to a pharmacologically inactive derivative of a parent drug molecule that requires biotransformation, either spontaneous or enzymatic, within the organism to release the active drug.
Prodrugs are variations or derivatives of the compounds of this invention which have groups cleavable under metabolic conditions. Prodrugs become the compounds of the invention which are pharmaceutically active in vivo, when they undergo solvolysis 1 S under physiological conditions or undergo enzymatic degradation. Prodrug compounds of this invention may be called single, double, triple etc., depending on the number of biotransformation steps required to release the active drug within the organism, and indicating the number of functionalities present in a precursor-type form. Prodrug forms often offer advantages of solubility, tissue compatibility, or delayed release in the mammalian organism (see, Bundgard, Design of Prodrugs, pp.
7-9, 21-24, Elsevier, Amsterdam 1985 and Silverman, The Organic Chemistry of Drug Design and Drug Action, pp. 352-401, Academic Press, San Diego, CA, 1992).
Prodrugs commonly known in the art include acid derivatives well known to practitioners of the art, such as, for example, esters prepared by reaction of the parent acids with a suitable alcohol, or amides prepared by reaction of the parent acid compound with an amine, or basic groups reacted to form an acylated base derivative. Moreover, the prodrug derivatives of this invention may be combined with other features herein taught to enhance bioavailability.
As mentioned above, the compounds of this invention find utility as therapeutic agents for disease states in mammals which have disorders of coagulation such as in the treatment or prevention of unstable angina, refractory angina, myocardial infarction, transient ischemic attacks, thrombotic stroke, embolic stroke, disseminated intravascular coagulation including the treatment of septic shock, deep venous thrombosis in the prevention of pulinonary embolism or the treatment of reocclusion or restenosis of reperfused coronary arteries.
Further, these compounds are useful for the treatment or prophylaxis of those diseases which involve the production and/or action of factor Xa/prothrombinase complex. This includes a number of thrombotic and prothrombotic states in which the coagulation cascade is activated which include but are not limited to, deep venous thrombosis, pulmonary embolism, myocardial infarction, stroke, thromboembolic complications of surgery and peripheral arterial occlusion.
Accordingly, a method for preventing or treating a condition in a mammal characterized by undesired thrombosis comprises administering to the mammal a therapeutically effective amount of a compound of this invention. In addition to the disease states noted above, other diseases treatable or preventable by the administration of compounds of this invention include, without limitation, occlusive coronary thrombus formation resulting from either thrombolytic therapy or percutaneous transluminal coronary angioplasty, thrombus formation in the venous vasculature, disseminated intravascular coagulopathy, a condition wherein there is rapid consumption of coagulation factors and systemic coagulation which results in the formation of life-threatening thrombi occurring throughout the microvasculature leading to widespread organ failure, hemorrhagic stroke, renal dialysis, blood oxygenation, and cardiac catheterization.
The compounds of the invention also find utility in a method for inhibiting the coagulation biological samples, which comprises the administration of a compound of the invention.
The compounds of the present invention may also be used in combination with other therapeutic or diagnostic agents. In certain preferred embodiments, the compounds of this invention may be coadministered along with other compounds typically prescribed for these conditions according to generally accepted medical practice such as anticoagulant agents, thrombolytic agents, or other antithrombotics, including platelet aggregation inhibitors, tissue plasminogen activators, urokinase, prourokinase, streptokinase, heparin, aspirin, or warfarin. The compounds of the present invention may act in a synergistic fashion to prevent reocclusion following a successful thrombolytic therapy and/or reduce the time to reperfusion. These compounds may also allow for reduced doses of the thrombolytic agents to be used and therefore minimize potential hemorrhagic side-effects. The compounds of this invention can be utilized in vivo, ordinarily in mammals such as primates, (e.g.

humans), sheep, horses, cattle, pigs, dogs, cats, rats and mice, or in vitro.
The biological properties of the compounds of the present invention can be readily characterized by methods that are well known in the art, for example by the in vitro protease activity assays and in vivo studies to evaluate antithrombotic S efficacy, and effects on hemostasis and hematological parameters, such as are illustrated in the examples.
Diagnostic applications of the compounds of this invention will typically utilize formulations in the form of solutions or suspensions. In the management of thrombotic disorders the compounds of this invention may be utilized in compositions such as tablets, capsules or elixirs for oral administration, suppositories, sterile solutions or suspensions or injectable administration, and the like, or incorporated into shaped articles. Subjects in need of treatment (typically mammalian) using the compounds of this invention can be administered dosages that will provide optimal efficacy. The dose and method of administration will vary from subject to subject and be dependent upon such factors as the type of mammal being treated, its sex, weight, diet, concurrent medication, overall clinical condition, the particular compounds employed, the specific use for which these compounds are employed, and other factors which those skilled in the medical arts will recognize.
Formulations of the compounds of this invention are prepared for storage or administration by mixing the compound having a desired degree of purity with physiologically acceptable carriers, excipients, stabilizers etc., and may be provided in sustained release or timed release formulations. Acceptable carriers or diluents for therapeutic use are well known in the pharmaceutical field, and are described, for example, in Remington's Pharmaceutical Sciences, Mack Publishing Co., (A.R.
Gennaro edit. 1985). Such materials are nontoxic to the recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, acetate and other organic acid salts, antioxidants such as ascorbic acid, low molecular weight (less than about ten residues) peptides such as polyarginine, proteins, such as serum albumin, gelatin, or immunoglobulins, hydrophilic polymers such as polyvinylpyrrolidinone, amino acids such as glycine, glutamic acid, aspartic acid, or arginine, monosaccharides, disaccharides, and other carbohydrates including cellulose or its derivatives, glucose, mannose or dextrins, chelating agents such as EDTA, sugar alcohols such as mannitol or sorbitol, counterions such as sodium and/or nonionic surfactants such as Tween, Pluronics or polyethyleneglycol.

Dosage formulations of the compounds of this invention to be used for therapeutic administration must be sterile. Sterility is readily accomplished by filtration through sterile membranes such as 0.2 micron membranes, or by other conventional methods. Formulations typically will be stored in lyophilized form or as an aqueous solution. The pH of the preparations of this invention typically will be 3-11, more preferably 5-9 and most preferably 7-8. It will be understood that use of certain of the foregoing excipients, carriers, or stabilizers will result in the formation of cyclic polypeptide salts. While the preferred route of administration is by injection, other methods of administration are also anticipated such as orally, intravenously (bolus and/or infusion), subcutaneously, intramuscularly, colonically, rectally, nasally, transdermally or intraperitoneally, employing a variety of dosage forms such as suppositories, implanted pellets or small cylinders, aerosols, oral dosage formulations and topical formulations such as ointments, drops and dermal patches. The compounds of this invention are desirably incorporated into shaped articles such as implants which may employ inert materials such as biodegradable polymers or synthetic silicones, for example, Silastic, silicone rubber or other polymers commercially available.
The compounds of the invention may also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles. Liposomes can be formed from a variety of lipids, such as cholesterol, stearylamine or phosphatidylcholines.
The compounds of this invention may also be delivered by the use of antibodies, antibody fragments, growth factors, hormones, or other targeting moieties, to which the compound molecules are coupled. The compounds of this invention may also be coupled with suitable polymers as targetable drug Garners.
Such polymers can include polyvinylpyrrolidinone, pyran copolymer, polyhydroxy-propyl-methacrylamide-phenol, polyhydroxyethyl-aspartamide-phenol, or polyethyleneoxide-polylysine substituted with palmitoyl residues. Furthermore, compounds of the invention may be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example polylactic acid, polyglycolic acid, copolymers of polylactic and polyglycolic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates and cross linked or amphipathic block copolymers of hydrogels. Polymers and semipermeable polymer matrices may be formed into shaped articles, such as valves, stems, tubing, prostheses and the like.
Therapeutic compound liquid formulations generally are placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by hypodermic injection needle.
Therapeutically effective dosages may be determined by either in vitro or in vivo methods. For each particular compound of the present invention, individual determinations may be made to determine the optimal dosage required. The range of therapeutically effective dosages will be influenced by the route of administration, the therapeutic objectives and the condition of the patient. For injection by hypodermic needle, it may be assumed the dosage is delivered into the body's fluids.
For other routes of administration, the absorption efficiency must be individually determined for each compound by methods well known in pharmacology.
Accordingly, it may be necessary for the therapist to titer the dosage and modify the route of administration as required to obtain the optimal therapeutic effect.
The determination of effective dosage levels, that is, the dosage levels necessary to achieve the desired result, will be readily determined by one skilled in the art.
Typically, applications of compound are commenced at lower dosage levels, with dosage levels being increased until the desired effect is achieved.
The compounds of the invention can be administered orally or parenterally in an effective amount within the dosage range of about 0.1 to 100 mg/kg, preferably about 0.5 to 50 mg/kg and more preferably about 1 to 20 mglkg on a regimen in a single or 2 to 4 divided daily doses and/or continuous infusion.
Typically, about 5 to S00 mg of a compound or mixture of compounds of this invention, as the free acid or base form or as a pharmaceutically acceptable salt, is compounded with a physiologically acceptable vehicle, carrier, excipient, binder, preservative, stabilizer, dye, flavor etc., as called for by accepted pharmaceutical practice. The amount of active ingredient in these compositions is such that a suitable dosage in the range indicated is obtained.
Typical adjuvants which may be incorporated into tablets, capsules and the like are binders such as acacia, corn starch or gelatin, and excipients such as microcrystalline cellulose, disintegrating agents like corn starch or alginic acid, lubricants such as magnesium stearate, sweetening agents such as sucrose or lactose, or flavoring agents. When a dosage form is a capsule, in addition to the above materials it may also contain liquid Garners such as water, saline, or a fatty oil.
Other materials of various types may be used as coatings or as modifiers of the physical form of the dosage unit. Sterile compositions for injection can be formulated according to conventional pharmaceutical practice. For example, dissolution or suspension of the active compound in a vehicle such as an oil or a synthetic fatty vehicle like ethyl oleate, or into a liposome may be desired.
Buffers, preservatives, antioxidants and the like can be incorporated according to accepted pharmaceutical practice.
Preparation of Com op unds The compounds of the present invention may be synthesized by either solid or liquid phase methods described and referenced in standard textbooks, or by a 1 S combination of both methods. These methods are well known in the art. See, Bodanszky, "The Principles of Peptide Synthesis", Hafner, et al., Eds., Springer-Verlag, Berlin, 1984.
Starting materials used in any of these methods are commercially available from chemical vendors such as Aldrich, Sigma, Nova Biochemicals, Bachem Biosciences, and the like, or may be readily synthesized by known procedures.
Reactions are carned out in standard laboratory glassware and reaction vessels under reaction conditions of standard temperature and pressure, except where otherwise indicated.
During the synthesis of these compounds, the functional groups of the amino acid derivatives used in these methods are protected by blocking groups to prevent cross reaction during the coupling procedure. Examples of suitable blocking groups and their use are described in "The Peptides: Analysis, Synthesis, Biology", Academic Press, Vol. 3 (Gross, et al., Eds., 1981) and Vol. 9 (1987), the disclosures of which are incorporated herein by reference.
Non-limiting exemplary synthesis schemes are outlined directly below, and specific steps are described in the Examples. The reaction products are isolated and purified by conventional methods, typically by solvent extraction into a compatible solvent. The products may be fiuther purified by column chromatography or other appropriate methods.
c em 1 H ~ ~ ~ H BuLi, [(CH3)zCHO]3B
W S_CI 2 S_N
O I / O 1 N HCI, THF
TEA DCM

HO, ,OH Pd(Ph3P)4, Bu4NBr, NaOH, toluene I
B
O ~
I / O H2N ~ ~ Br I ~ S-NH~
~O
a 2 N HtB a COzH HzN ~ O-S-O
O O
O
N OMe OMe CN
HCI. HN i BOP, DIEA, DMF CN AIMe3, DCM
O O SOZNHtBu _ _ 1. HCI, MeOH
~NH ~ ~ ~ ~ 2. NH40Ac, MeOH
C /~/7N
O O SOZNHz ~NH
HN NHz Scheme 3 Br + ~ pdz(dbay~, (s?-BINAP I ~ N~ T~ ~ N
N COOtBu NaOtBu, toluene, 90°C ~ COOtBu ~ , COOH
H
CN CN CN
O
~ r NH2 / \ ~~ . ' SOzNHtBu \ / H ~~~ ~ TFA / \ \ /
'-' ~J
BOP, Et3N, DMF SOZNHtBu ' % SOZNHZ \ ~ N

1.NHzOH.HCI, Et3N, ethanol, 40 °C / \
2.Ao20, AcOH
3.50psi H2, 10%Pd/C, methanol SOZNHz HZN NH
c a e4 ~ Br + Pd2(dbay~, (srBINAP ~ N~ T~ ~ N
i ~COOtBu NaOtBu, toluene, 90°C I ~ COOtBu ~ , COO
CN H CN CN
r v ~ r N~
N S~~ / ~ N~,~..
SOGz, methanol ~ 2 \ / H
COOMe AIMS, DCM
SOzN HtBu O CN
1.HC1, methanol -2.NH40Ac, methanol, reflux / ~ N~~,,~.
/ H I~N
SOZNHz F

HZN ~NH

Scheme 5 r v ~ , N H2 Br N' J F
Pd2(dbay~, (s~BINAP_ I ~ TI SOZNHtBu 'N"COOEt NaOtBu, toluene, 90°C i COOEt AIMe3, DCM
CN H CN
CN N
NH
O
N 1.H2S, Py, Et3N O
2.Mel, Acetone - 3.NH40Ac, methanol ~ \ N N
SOZNHtBu F 4.TFA, reflux \ / H
SOZNHZ F
the r v ~, Nhh Br + Pd2(dba~, (s~BINAP_ I ~ N SOpNHtBu ~COOEt NaOtBu, toluene, 90°C ~ COOEt AIM DCM
CN H CN
CN N
O 'NH
/ \ N I.HzS, Py, Et3N O I r 2.Mel, Acetone 3.NH40Ac, methanol ~ \ N N
SOzNHtBu CI 4.TFA, reflux \ ~ H
SOzNI-t~ CI

ce Br ~ Pd2(dbay~, (s}~BINAP w N~ TFA w N
+ ~COOtBu o ~ , COOtBu ~ COOH
NaOtBu, toluene, 90 C I i CN H CN CN
~r_v ~ i NHz L
N SO NHfBu / \ N~ '~~.
SOG2, methand ~ 2 \ / H
COOMe ~M ,DCM
CN ~ S02NHtBu C11 ~
CN
1.HC1, methanol 2.NH40Ac, methanol, reflux eme 8 r v ~ , N~
Br Pd2(dbay~, (srBINAP ~ N SazNHtBu ~COOEt NaOtBu, tduene, 90°C ~ COOEt AIM DCM
CN H CN
CN
O
1.NH20H.HG, Et3N, ethanol, 40 °C
/ \ \ / N N 2Acz0, AcOH
H 3.50psi Hz, 10%Pd/C, methand 4.TFA, reflux S4zN HBu Compositions and Formulations The compounds of this invention may be isolated as the free acid or base or converted to salts of various inorganic and organic acids and bases. Such salts are within the scope of this invention. Non-toxic and physiologically compatible salts are particularly useful although other less desirable salts may have use in the processes of isolation and purification.
A number of methods are useful for the preparation of the salts described above and are known to those skilled in the art. For example, reaction of the free acid or free base form of a compound of the structures recited above with one or more molar equivalents of the desired acid or base in a solvent or solvent mixture in which the salt is insoluble, or in a solvent like water after which the solvent is removed by evaporation, distillation or freeze drying. Alternatively, the free acid or base form of the product may be passed over an ion exchange resin to form the desired salt or one salt form of the product may be converted to another using the same general process.
Diagnostic applications of the compounds of this invention will typically utilize formulations such as solution or suspension. In the management of thrombotic disorders the compounds of this invention may be utilized in compositions such as tablets, capsules or elixirs for oral administration, suppositories, sterile solutions or suspensions or injectable administration, and the like, or incorporated into shaped articles. Subjects in need of treatment (typically mammalian) using the compounds of this invention can be administered dosages that will provide optimal efficacy. The dose and method of administration will vary from subject to subject and be dependent upon such factors as the type of mammal being treated, its sex, weight, diet, concurrent medication, overall clinical condition, the particular compounds employed, the specific use for which these compounds are employed, and other factors which those skilled in the medical arts will recognize.
Formulations of the compounds of this invention are prepared for storage or administration by mixing the compound having a desired degree of purity with physiologically acceptable carriers, excipients, stabilizers etc., and may be provided in sustained release or timed release formulations. Acceptable carriers or diluents for therapeutic use are well known in the pharmaceutical field, and are described, for example, in Remington's Pharmaceutical Sciences, Mack Publishing Co., (A.R.
Gennaro edit. 1985). Such materials are nontoxic to the recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, acetate and other organic acid salts, antioxidants such as ascorbic acid, low molecular weight (less than about ten residues) peptides such as polyarginine, proteins, such as serum albumin, gelatin, or immunoglobulins, hydrophilic polymers such as polyvinalpyrrolidinone, amino acids such as glycine, glutamic acid, aspartic acid, or arginine, monosaccharides, disaccharides, and other carbohydrates including cellulose or its derivatives, glucose, mannose or dextrins, chelating agents such as EDTA, sugar alcohols such as mannitol or sorbitol, counterions such as sodium and/or nonionic surfactants such as Tween, Pluronics or polyethyleneglycol.
Dosage formulations of the compounds of this invention to be used for therapeutic administration must be sterile. Sterility is readily accomplished by filtration through sterile membranes such as 0.2 micron membranes, or by other conventional methods. Formulations typically will be stored in lyophilized form or as an aqueous solution. The pH of the preparations of this invention typically will be between 3 and 11, more preferably from 5 to 9 and most preferably from 7 to 8.
It will be understood that use of certain of the foregoing excipients, carriers, or stabilizers will result in the formation of cyclic polypeptide salts. While the preferred route of administration is by injection, other methods of administration are also anticipated such as intravenously (bolus and/or infusion), subcutaneously, intramuscularly, colonically, rectally, nasally or intraperitoneally, employing a variety of dosage forms such as suppositories, implanted pellets or small cylinders, aerosols, oral dosage formulations and topical formulations such as ointments, drops and dermal patches. The compounds of this invention are desirably incorporated into shaped articles such as implants which may employ inert materials such as biodegradable polymers or synthetic silicones, for example, Silastic, silicone rubber or other polymers commercially available.
The compounds of this invention may also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles. Liposomes can be formed from a variety of lipids, such as cholesterol, stearylamine or phosphatidylcholines.
The compounds of this invention may also be delivered by the use of antibodies, antibody fragments, growth factors, hormones, or other targeting moieties, to which the compound molecules are coupled. The compounds of this invention may also be coupled with suitable polymers as targetable drug carriers.
Such polymers can include polyvinylpyrrolidone, pyran copolymer, polyhydroxy-propyl-methacrylamide-phenol, polyhydroxyethyl-aspartamide-phenol, or polyethyleneoxide-polylysine substituted with palmitoyl residues. Furthermore, the factor Xa inhibitors of this invention may be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example polylactic acid, polyglycolic acid, copolymers of polylactic and polyglycolic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates and cross linked or amphipathic block copolymers of hydrogels. Polymers and semipermeable polymer matrices may be formed into shaped articles, such as valves, stems, tubing, prostheses and the like.
Therapeutic compound liquid formulations generally are placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by hypodermic injection needle.
Therapeutically effective dosages may be determined by either in vitro or in vivo methods. For each particular compound of the present invention, individual determinations may be made to determine the optimal dosage required. The range of therapeutically effective dosages will naturally be influenced by the route of administration, the therapeutic objectives, and the condition of the patient.
For injection by hypodermic needle, it may be assumed the dosage is delivered into the body's fluids. For other routes of administration, the absorption efficiency must be individually determined for each inhibitor by methods well known in pharmacology.
Accordingly, it may be necessary for the therapist to titer the dosage and modify the route of administration as required to obtain the optimal therapeutic effect.
The determination of effective dosage levels, that is, the dosage levels necessary to achieve the desired result, will be within the ambit of one skilled in the art.
Typically, applications of compound are commenced at lower dosage levels, with dosage levels being increased until the desired effect is achieved.
A typical dosage might range from about 0.001 mg/kg to about 1000 mg/kg, preferably from about 0.01 mg/kg to about 100 mg/kg, and more preferably from about 0.10 mg/kg to about 20 mg/kg. Advantageously, the compounds of this invention may be administered several times daily, and other dosage regimens may also be useful.

Typically, about 0.5 to 500 mg of a compound or mixture of compounds of this invention, as the free acid or base form or as a pharmaceutically acceptable salt, is compounded with a physiologically acceptable vehicle, Garner, excipient, binder, preservative, stabilizer, dye, flavor etc., as called for by accepted pharmaceutical S practice. The amount of active ingredient in these compositions is such that a suitable dosage in the range indicated is obtained.
Typical adjuvants which may be incorporated into tablets, capsules and the like are a binder such as acacia, corn starch or gelatin, and excipient such as microcrystalline cellulose, a disintegrating agent like corn starch or alginic acid, a lubricant such as magnesium stearate, a sweetening agent such as sucrose or lactose, or a flavoring agent. When a dosage form is a capsule, in addition to the above materials it may also contain a liquid carrier such as water, saline, a fatty oil. Other materials of various types may be used as coatings or as modifiers of the physical form of the dosage unit. Sterile compositions for injection can be formulated according to conventional pharmaceutical practice. For example, dissolution or suspension of the active compound in a vehicle such as an oil or a synthetic fatty vehicle like ethyl oleate, or into a liposome may be desired. Buffers, preservatives, antioxidants and the like can be incorporated according to accepted pharmaceutical practice.
In practicing the methods of this invention, the compounds of this invention may be used alone or in combination, or in combination with other therapeutic or diagnostic agents. In certain preferred embodiments, the compounds of this inventions may be coadministered along with other compounds typically prescribed for these conditions according to generally accepted medical practice, such as anticoagulant agents, thrombolytic agents, or other antithrombotics, including platelet aggregation inhibitors, tissue plasminogen activators, urokinase, prourokinase, streptokinase, heparin, aspirin, or warfarin. The compounds of this invention can be utilized in vivo, ordinarily in mammals such as primates, such as humans, sheep, horses, cattle, pigs, dogs, cats, rats and mice, or in vitro.
The preferred compounds of the present invention are characterized by their ability to inhibit thrombus formation with acceptable effects on classical measures of coagulation parameters, platelets and platelet function, and acceptable levels of bleeding complications associated with their use. Conditions characterized by undesired thrombosis would include those involving the arterial and venous vasculature.
With respect to the coronary arterial vasculature, abnormal thrombus formation characterizes the rupture of an established atherosclerotic plaque which is the major cause of acute myocardial infarction and unstable angina, as well as also characterizing the occlusive coronary thrombus formation resulting from either thrombolytic therapy or percutaneous transluminal coronary angioplasty (PTCA).
With respect to the venous vasculature, abnormal thrombus formation characterizes the condition observed in patients undergoing major surgery in the lower extremities or the abdominal area who often suffer from thrombus formation in the venous vasculature resulting in reduced blood flow to the affected extremity and a predisposition to pulmonary embolism. Abnormal thrombus formation further characterizes disseminated intravascular coagulopathy commonly occurs within both vascular systems during septic shock, certain viral infections and cancer, a condition wherein there is rapid consumption of coagulation factors and systemic coagulation which results in the formation of life-threatening thrombi occurring throughout the microvasculature leading to widespread organ failure.

The compounds of this present invention, selected and used as disclosed herein, are believed to be useful for preventing or treating a condition characterized by undesired thrombosis, such as (a) the treatment or prevention of any thrombotically mediated acute coronary syndrome including myocardial infarction, unstable angina, refractory angina, occlusive coronary thrombus occurnng post-thrombolytic therapy or post-coronary angioplasty, (b) the treatment or prevention of any thrombotically mediated cerebrovascular syndrome including embolic stroke, thrombotic stroke or transient ischemic attacks, (c) the treatment or prevention of any thrombotic syndrome occurring in the venous system including deep venous thrombosis or pulmonary embolus occurring either spontaneously or in the setting of malignancy, surgery or trauma, (d) the treatment or prevention of any coagulopathy including disseminated intravascular coagulation (including the setting of septic shock or other infection, surgery, pregnancy, trauma or malignancy and whether 1 S associated with multi-organ failure or not), thrombotic thrombocytopenic purpura, thromboangiitis obliterans, or thrombotic disease associated with heparin induced thrombocytopenia, (e) the treatment or prevention of thrombotic complications associated with extracorporeal circulation (e.g. renal dialysis, cardiopulmonary bypass or other oxygenation procedure, plasmapheresis), (f) the treatment or prevention of thrombotic complications associated with instrumentation (e.g.
cardiac or other intravascular catheterization, intra-aortic balloon pump, coronary stmt or cardiac valve), and (g) those involved with the fitting of prosthetic devices.
Anticoagulant therapy is also useful to prevent coagulation of stored whole blood and to prevent coagulation in other biological samples for testing or storage.
Thus the compounds of this invention can be added to or contacted with any medium containing or suspected to contain factor Xa and in which it is desired that blood coagulation be inhibited, e.g., when contacting the mammal's blood with material such as vascular grafts, stems, orthopedic prostheses, cardiac stents, valves and prostheses, extra corporeal circulation systems and the like.
Without further description, it is believed that one of ordinary skill in the art can, using the preceding description and the following illustrative examples, make and utilize the compounds of the present invention and practice the claimed methods. The following working examples therefore, specifically point out preferred embodiments of the present invention, and are not to be construed as limiting in any way the remainder of the disclosure.
EXAMPLES
Exam N
,COOtBu CN
To a solution of 3-bromobenzonitrile (2.73g, l5mmol), H(L)-Proline-OtBu (5.14g, 30mmo1), sodium tert-butoxide (2.02g, 2lmmol) and (s)-(-)2,2'-bis(diphenylphosphino)-1,1'-binaphthyl (186mg, 0.3mmo1) in toluene (30m1) was added tris(dibenzylideneactone)dipalladium (0) (137mg, O.l5mmol). The mixture was stirred at 90 °C for 6 hrs. After the filtration of the solid, the filtrate was concentrated in vacuo. The residue was purified by silica gel column chromatography using solvent system 10% ethyl acetate in hexane as eluent to give the title compound as a light yellowish oil (336mg, 82%). ES-MS (M+H)+ = 273.

E a N

CN
The compound of example 1 (1.4g, S.l5mmol) was dissolved in trifluoroacetic acid (5m1). The mixture was stirred at room temperature for 5 hrs. The solvent was evaporated in vacuo to give the title compound (1.14g, 100%). ES-MS (M+H)+ _ 217.
am 1e 3 / \
S02NHtBu To a solution of tert-butylamine (5.73g, 78.4mmo1) and triethylamine (16.6m1, 1 l9mmol) in dichloromethane (200m1) in an ice bath was added benzenesulfonyl chloride (13.85g, 78.4mmo1) dropwise. The mixture was stirred at room temperature overnight. It was washed with saturated sodium carbonate (60m1) and brine (60m1).
The organic layer was separated, and the aqueous layer was extracted with dichloromethane (2xSOm1). The combined organic extracts were dried over magnesium sulfate. The solvent was evaporated in vacuo to give the title compound as a light yellowish solid (15.92g, 95%). ES-MS (M+H)+ = 214.
Example 4 / \ B~oHn S02NHtBu To a solution of the compound of example 3 (15.92g, 74.7mmo1) in tetrahydrofuran (200m1) in an ice bath was added 1.6M n-butyllithium in hexane (100m1, 164mmo1) dropwise over 30 minutes. The mixture remained a clear solution. In an ice bath it was added triisopropylborate (24.1m1, 104mmo1) dropwise. The mixture was stirred at room temperature for 3.Shrs, solution becoming cloudy. After it was cooled in an ice bath, 1N hydrochloride (200m1) was added. The mixture was stirred at room temperature overnight. It was extracted with ether (2x50m1). The organic extract was washed with 1N sodium hydroxide (2x60m1). The aqueous solution was acidified to pH=1 with 6N hydrochloride, and then extracted with ether (2x100m1). The ether extract was dried over magnesium sulfate, and concentrated in vacuo. The crude product was recrystallized by ether and hexane to give the title compound as a while solid (1 1.5g, 60%). ES-MS (M+H)+ = 258.
Example 5 / \ \ / NHz S02NHtBu To a solution of the compound of example 4 (6.4g, 25mmo1) in toluene (120m1) was added water (15m1), SN sodium hydroxide (40m1), isopropanol (60m1), 4-bromoaniline (8.57g, SOmmol) and tetrakis(triphenylphosphine)palladium (0) (1,44g, 1.25mmo1). The mixture was refluxed for 6 hrs, cooled to room temperature, and diluted with ethyl acetate. The organic layer was washed with water (SOmI), and dried over magnesium sulfate. After the evaporation of the solvent in vacuo, the crude reside was purified by silica gel chromatography using solvent system 30%
ethyl acetate in hexane as eluent to give the title compound as a light yellowish solid (5g, 66%). ES-MS (M+H)+ = 305.
e6 / \ N~II~~, \ / H N
SOzNHtBu 1 CN
To a solution of the compound of example 2 (216mg, lmmol) in dimethylformamide (5m1) was added triethylamine (279u1, 2mmo1), the compound of example S
(304mg.
lmmol) and the coupling reagent BOP (531mg, l.2mmo1). The mixture was stirred at room temperature overnight. After the evaporation of the solvent in vacuo, the crude~product was purified by silica gel column chromatography using solvent system 30-50% ethyl acetate in hexane as eluent to give the title compound as an oil (220mg, 44%). ES-MS (M+H)+ = 503.

N

CN
The compound of example 6 (220mg, 0,44mmol) was dissolved in trifluoroacetic acid (3m1). The mixture was refluxed for l.Shrs. The solvent was evaporated in vacuo to give the title compound as an oil (200mg, 100%). MS-ES (M+H)+ = 447.
Exam 1 N~l'"~~
/ H N

A solution of the compound of example 7 (200mg, 0.44mmol), hydroxylamine hydrochloride (76mg, l.lmmol) and triethylamine (153u1, l.lmmol) in absolute 1 S ethanol (3m1) was stirred at 40 °C for 15 hrs. After the evaporation of the solvent in vacuo, the residue was dissolved in acetic acid (2m1), and acetic anhydride (83u1, 0,88mmo1) was added. The mixture was stirred at room temperature for 3 hrs. It was diluted with absolute methanol (5m1), and 10% Pd/C (catalytic amount) was added.
The mixture was applied with SOpsi hydrogen for 6 hrs. After the filtration through Celite to remove the catalyst, the filtrate was concentrated in vacuo. The crude residue was purified by RP-HPLC to give the title compound as a white powder (89mg, 46%). ES-MS (M+H)+ = 464.

xam 1e N
1COOMe CN
To a solution of the compound of example 2 (210mg, lmmol) in methanol (5m1) in an ice bath was added thionyl chloride (142u1, 2mmo1) dropwise. The mixture was stirred at room temperature overnight. After the concentration in vacuo, it was dissolved in dichloromethane (lOml), and washed with water (5m1). The organic extract was dried over magnesium sulfate, and concentrated in vacuo to give the title 1 S compound as an oil (290mg, 100%). ES-MS (M+H)+ = 231.
Exam 1ne10 SOZNHtBu F
To a solution of the compound of example 4 (2.06g, 8mmo1) in toluene (60m1) was added water (4m1), 8N sodium hydroxide (8m1), isopropanol (16m1), 2-fluoro-4-iodoaniline (3.8g, l6mmol) and tetrakis(triphenylphosphine)palladium (0) (464mg, 0.4mmo1). The mixture was refluxed for 3-4 hrs, cooled to room temperature, and diluted with ethyl acetate. The organic layer was washed with water (25m1), and dried over magnesium sulfate. After the evaporation of the solvent in vacuo, the crude reside was purified by silica gel column chromatography using solvent system 20-30% ethyl acetate in hexane as eluent to give the title compound as a white solid (1.49g, 58%). ES-MS (M+H)+=323.

Example 11 / \ - N~~r., \ / H N
S02NHtBu F 1 ~
CN
To a solution of the compound of example 10 (110mg, 0.34mmol) in dichloromethane (5m1) was added 2.0M trimethylaluminum in hexane (O.Slml, 1.02mmo1). The mixture was stirred at room temperature for 30 minutes, methane gas evolved. A solution of the compound of example 9 (78mg, 0.34mmo1) in dichloromethane (1m1) was added. The mixture was stirred at room temperature overnight. 1N hydrochloride was added to acidify the solution to pH=2. After the addition of water and dichloromethane, the organic layer was separated, and the aqueous layer was extracted with dichloromethane. The combined organic extracts were dried over magnesium sulfate, and concentrated in vacuo. The crude residue was purified by silica gel column chromatography using solvent system 25%
ethyl acetate in hexane as eluent to give the title compound as a solid (90mg, 51 %). ES-MS (M+H)+ = 521.
Example 12 / \ - N~~~-., \ / H NN

HZN -NH
To a solution of the compound of example 11 (90mg, 0.17mmo1) in absolute methanol (3m1) in an ice bath was saturated with hydrochloride gas for 10 minutes.
The mixture was stirred at room temperature for 3 hrs. After the evaporation of the solvent in vacuo, the residue was dissolved in absolute methanol (3m1), and ammonia acetate (80mg, 1.04mmo1) was added. The mixture was refluxed for 3 hrs.

The solvent was evaporated in vacuo. The crude residue was purified by RP-HPLC
to give the title compound as a white powder (36mg, 44%). ES-MS (M+H)+ = 482.
Example 13 / \ \ / NH2 S02NHtBu CI
To a solution of the compound of example 4 (2.06g, 8mmol) in toluene (60m1) was added water (4m1), 8N sodium hydroxide (8m1), isopropanol (16m1), 2-chloro-4-iodoaniline (4.06g, l6mmol) and tetrakis(triphenylphosphine)palladium(0) (464mg, 0.4mmo1). The mixture was refluxed for 3-4 hrs, cooled to room temperature, and diluted with ethyl acetate. The organic layer was washed with water (25m1), and dried over magnesium sulfate. After the evaporation of the solvent in vacuo, the crude reside was purified by silica gel column chromatography using solvent system 20-30% ethyl acetate in hexane as eluent to give the title compound as a white solid (1.43g, 53%). ES-MS (M+H)+ = 339.
Example 14 / \ - N~~r., \ / H N
SOzNHtBu CI1 ~
CN
To a solution of the compound of example 13 (147mg, 0.43mmo1) in dichloromethane (5m1) was added 2.0M trimethylaluminum in hexane (0.65m1, 1.30mmo1). The mixture was stirred at room temperature for 30 minutes, methane gas evolved. A solution of the compound of example 9 (100mg, 0.43mmo1) in dichloromethane (1m1) was added. The mixture was stirred at room temperature overnight. 1N hydrochloride was added to acidify the solution to pH=2. After the addition of water and dichloromethane, the organic layer was separated, and the aqueous layer was extracted with dichloromethane. The combined organic extracts were dried over magnesium sulfate, and concentrated in vacuo. The crude residue was purified by silica gel column chromatography using solvent system 25%
ethyl acetate in hexane as eluent to give the title compound as a solid (180mg, 78%). ES-MS (M+H)+ = 537.
Example 15 To a solution of the compound of example 14 (180mg, 0.34mmo1) in absolute methanol (3m1) in an ice bath was saturated with hydrochloride gas for 10 minutes.
The mixture was stirred at room temperature for 3 hrs. After the evaporation of the solvent in vacuo, the residue was dissolved in absolute methanol (3m1), and ammonia acetate (155mg, 2mmo1) was added. The mixture was refluxed for 3 hrs.
The solvent was evaporated in vacuo. The crude residue was purified by RP-HPLC
to give the title compound as a white powder (SSmg, 33%). ES-MS (M+H)+ = 498.
Example 16 N
COOEt CN
To a solution of 3-bromobenzonitrile (1.82g, lOmmol), ethyl pipecolinate (3.148, 20mmo1), sodium tent-butoxide (1.35g, l4mmol) and (s)-(-)2,2'-bis (diphenylphosphino)-1,1'-binaphthyl (125mg, 0.2mmo1) in toluene (20m1) was added tris(dibenzylideneactone)dipalladium (0) (92mg, O.lmmol). The mixture was stirred at 90 °C for 6 hrs. After the filtration of the solid, the filtrate was concentrated in vacuo. The residue was purified by silica gel column chromatography using solvent system 5-10% ethyl acetate in hexane as eluent to give the title compound as an oil (770mg, 30%). ES-MS (M+H)+ = 259.

Exam 1p a 17 CN
O
N
H
S02NHtBu To a solution of the compound of example S (189mg, 0.62mmo1) in dichloromethane (2m1) was added 2.0M trimethylaluminum in hexane (0.93m1, 1.86mmo1). The mixture was stirred at room temperature for 30 minutes, methane gas evolved. A solution of the compound of example 16 (160mg, 0.62mmo1) in dichloromethane (1m1) was added. The mixture was stirred at rood temperature overnight. 1N hydrochloride was added to acidify the solution to pri=2. After the addition of water and dichloromethane, the organic layer was separated, and the aqueous layer was extracted with dichloromethane. The combined organic extracts were dried over magnesium sulfate, and concentrated in vacuo to give the title compound as a yellow solid (330mg, 100%). ES-MS (M+H)+ = S 17.
Example 18 NHZ
~NH
O
N
N
H

A solution of the compound of example 17 (330mg, 0.64mmo1), hydroxylamine hydrochloride (110mg, l.6mmo1) and triethylamine (223u1, l.6mmol) in absolute ethanol (lOml) was stirred at 40 °C for 15 hrs. After the evaporation of the solvent in vacuo, the residue was dissolved in acetic acid (4m1), and acetic anhydride (121u1, 1.28mmo1) was added. The mixture was stirred at room temperature for 3 hrs. It was diluted with absolute methanol (7m1), and 10% Pd/C (catalytic amount) was added.
The mixture was applied with SOpsi hydrogen for 6 hrs. After the filtration through Celite to remove the catalyst, the filtrate was concentrated in vacuo. The residue was dissolved in trifluoroacetic acid (5m1). The mixture was refluxed for l.Shrs.
After the evaporation of the solvent in vacuo, the crude residue was purified by RP-HPLC
to give the title compound as a white powder (200mg, 62%). ES-MS (M+H)+ = 478.
Example 19 CN
O
/ ~ - N
H
S02NHtBu F
To a solution of the compound of example 10 (125mg, 0.39mmo1) in dichloromethane (5m1) was added 2.0M trimethylaluminum in hexane (0.58m1, 1.16mmo1). The mixture was stirred at room temperature for 30 minutes, methane gas evolved. A solution of the compound of example 16 (100mg, 0.39mmo1) in dichlodomethane (1m1) was added. The mixture was stirred at room temperature overnight. 1N hydrochloride was added to acidify the solution to pH=2. After the 1 S addition of water and dichloromethane, the organic layer was separated and the aqueous layer was extracted with dichloromethane. The combined organic extracts were dried over magnesium sulfate, and concentrated in vacuo. The crude residue was purified by silica gel column chromatography using solvent system 20%
ethyl acetate in hexane as eluent to give the title compound as a solid (150mg, 72%). ES-MS (M+H)+ = 535.
Example 20 NH
w ,NH2 O
- N
H
SOZNHz F
To a solution of the compound of example 19 (100mg, 0.19mmol) and triethylamine (1m1) in absolute pyridine (lOml) was saturated with hydrosulfide gas for lOminutes.
The mixture was stirred at room temperature for 1 S hrs. After the evaporation of the solvent in vacuo, the green residue was dissolved in acetone (lOml).
Iodomethane (118u1, l.9mmo1) was added. The mixture was refluxed for lhr. After the evaporation of the solvent in vacuo, the residue was dissolved in absolute methanol (15m1), and ammonia acetate (176mg, 3.28mmol) was added. The mixture was refluxed for 3 hrs. After the concentration in vacuo, the residue was dissolved in trifluoroacetic acid (5m1), and was refluxed for lhr. The solvent was evaporated in vacuo. The crude residue was purified by RP-HPLC to give the title compound as a white powder. ES-MS (M+H)+ = 496.
Example 21 CN
O
N
H
SOZNHtBu CI
To a solution of the compound of example 13 (132mg, 0.39mmol) in dichloromethane (5m1) was added 2.0M trimethylaluminum in hexane (0.58m1, 1.l7mmol). The mixture was stirred at room temperature for 30 minutes, methane gas evolved. A solution of the compound of example 16 (100mg, 0.39mmo1) in dichloromethane (1m1) was added. The mixture was stirred at room temperature overnight. 1N hydrochloride solution was added to acidify the solution to pH=2.
After the addition of water and dichloromethane, the organic layer was separated, and the aqueous layer was extracted with dichloromethane. The combined organic extracts were dried over magnesium sulfate, and concentrated in vacuo. The crude residue was purified by silica gel column chromatography using solvent system 20%
ethyl acetate in hexane as eluent to give the title compound as an oil (160mg, 75%).
ES-MS (M+H)+ = 551.
Ex x In a 22 NH
O
- N
H
SOZNH2 C~

- 1$2 -To a solution of the compound of example 21 (100mg, 0.18mmo1) and triethylamine (1m1) in absolute pyridine (lOml) was saturated with hydrosulfide gas for lOminutes.
The mixture was stirred at room temperature for 1$ hrs. After the evaporation of the solvent in vacuo, the green residue was dissolved in acetone (lOml).
Iodomethane $ (112u1, l.8mmo1) was added. The mixture was refluxed for lhr. After the evaporation of the solvent in vacuo, the residue was dissolved in absolute methanol (1$m1), and ammonia acetate (166mg, 2.16mmol) was added. The mixture was refluxed for 3 hrs. After the evaporation of the solvent in vacuo, the residue was dissolved in trifluoroacetic acid ($m1), and was refluxed for lhr. The solvent was evaporated in vacuo. The crude residue was purified by RP-HPLC to give the title compound as a white powder. ES-MS (M+H)+ _ $12.
Exam 1p a 23 H O
N v _OEt i CN
1$
To a solution of ethyl bromoacetate (10.6g, 60mmo1), 3-aminobenzonitrile ($g, 40mmo1), and potassium carbonate (17.$g, 120mmo1) in acetonitrile (30m1) was added potassium iodide (1.4g, 8mmo1). The mixture was heated to reflex for 6 hrs.
The mixture was cooled to room temperature, and solvent was removed in vacuo.
Ether and water were added to the mixture. Organic layer was washed with 1N
hydrochloride and brine, and dried over magnesium sulfate. After the concentration in vacuo, the crude residue was purified by silica gel column chromatography using solvent system 1$% ethyl acetate in hexane as eluent to give the title compound as light yellowish solid (7.94g, 97%). ES-MS (M+H)+ = 20$.
2$
Example 24 I_ o N v _OEt CN
To a solution of the compound of example 23 (200mg, lmmol) and cesium carbonate (6$Omg, 2mmol) in dimethylformamide ($m1) was added iodomethane (7$u1, 1.2mmol). The mixture was stirred at 90 °C for 2 hrs. After the filtration of the solid, the filtrate was concentrated in vacuo, and the residue was purified by silica gel column chromatography using solvent system 15% ethyl acetate in hexane as eluent to give the title compound as an oil (270mg, 100%). ES-MS (M+H)+ = 219.
Example 25 ~ ~ / H~N
'-'' ~' S02NHtBu CN
To a solution of the compound of example 5 (126mg, 0.41mmo1) in dichloromethane (5m1) was added 2.0M trimethylaluminum in hexane (0.62m1, 1.24mmo1). The mixture was stirred at room temperature for 30 minutes, methane gas evolved. A solution of the compound of example 24 (90mg, 0.41mmo1) in dichlodomethane (1m1) was added. The mixture was stirred at room temperature overnight. 1N hydrochloride was added to acidify the solution to pH=2. After the addition of water and dichloromethane, the organic layer was separated and the aqueous layer was extracted with dichloromethane. The combined organic extracts were dried over magnesium sulfate, and concentrated in vacuo. The crude residue was purified by silica gel column chromatography using solvent system 30%
ethyl acetate in hexane as eluent to give the title compound as a solid (70mg, 36%).
ES-MS (M+H)+ = 477.
Example 26 _ II I
N
H
S02NHtBu HZN NH
A solution of the compound of example 25 (70mg, 0. l5mmol), hydroxylamine hydrochloride (26mg, 0.37mmo1) and triethylamine (52u1, 0.37mmo1) in absolute ethanol (3m1) was stirred at 40 °C for 15 hrs. After the evaporation of the solvent in vacuo, the residue was dissolved in acetic acid (3m1), and acetic anhydride (28u1, 0.3mmol) was added. The mixture was stirred at room temperature for 3 hrs. It was diluted with absolute methanol (5m1), and 10% Pd/C (catalytic amount) was added.
The mixture was applied with 50psi hydrogen for 6 hrs. After the filtration through Celite to remove the catalyst, the filtrate was concentrated in vacuo. The crude residue was purified by RP-HPLC to give the title compound as a white powder.
ES-MS (M+H)+ = 494.
Ex~ lie 27 Bn O
N v 'OEt CN
To a solution of the compound of example 23 (200mg, lmmol) and cesium carbonate (650mg, 2mmol) in dimethylformamide (5m1) was added benzyl bromide (180u1, l.Smmo1). The mixture was stirred at 90 °C for 2 hrs. After the filtration of the solid, the filtrate was concentrated in vacuo and the residue was purified by silica gel column chromatography using solvent system 10% ethyl acetate in hexane as eluent to give the title compound as an oil (210mg, 71 %). ES-MS (M+H)+ = 295.
Example 28 O Bn ~ ~ / H~N
S02NHtBu CN
To a solution of the compound of example 5 (126mg, 0.41mmo1) in dichloromethane (5m1) was added 2.0M trimethylaluminum in hexane (0.62m1, 1.24mmo1). The mixture was stirred at room temperature for 30 minutes, methane gas evolved. A solution of the compound of example 27 (120mg, 0.4~1mmo1) in dichlodomethane (1m1) was added. The mixture was stirred at room temperature overnight. 1N hydrochloride was added to acidify the solution to pH=2. After the addition of water and dichloromethane, the organic layer was separated, and the aqueous layer was extracted with dichloromethane. The combined organic extracts were dried over magnesium sulfate, and concentrated in vacuo. The crude residue was purified by silica gel column chromatography using solvent system 20%
ethyl acetate in hexane as eluent to give the title compound as a solid (172mg, 76%). ES-MS (M+H)+ = 553.

Example 29 OI Bn N
H

HZN NH
To a solution of the compound of example 28 (100mg, 0.18mmo1) and absolute S methanol (73u1, l.8mmo1) in ethyl acetate (3m1) in an ice bath was saturated with hydrochloride gas for 10 minutes. The mixture was stirred at room temperature for 3 hrs. After the evaporation of the solvent in vacuo, the residue was dissolved in absolute methanol (3m1), and ammonia acetate (83mg, 1.08mmo1) was added. The mixture was refluxed for 3 hrs. The solvent was evaporated in vacuo. The crude residue was purified by RP-HPLC to give the title compound as white powder. ES-MS (M+H)+ = 514.
Example 30 O O
N '~~H~OMe CN
H-Pro-OMe (3.38 g, 20.4 mmol) and 3-cyano-benzoic acid (3 g, 20.4 mmol) were dissolved in DMF (100 mL). DIEA (7.28 mL, 40.8 mmol) was added followed by the addition of the coupling reagent BOP (9.03 g, 20.4 mmol). The solution was stirred at room temperature for 12 hours. The reaction mixture was diluted in a mixture of EtOAc1H20 (100 mL:40 mL). The organic layer was washed with water, sat. NaHC03, water, brine, dried over MgS04, filtered and solvent evaporated.
The residue was purified by silica gel column chromatography using solvent system 20%
hexane in EtOAc as eluant to give the title compound. ES-MS (M+H)+ = 259Ø
Example 31 S02NHtBu = 156 -To a solution of tent-Butylamine (41.4g, 566 mmol) and triethylamine (118 mL, mmol) in DCM (1000 mL) in an ice bath, was added benzenesulfonyl chloride (100 g, 566 mmol) dropwise. The mixture was stirred at room temperature overnight.
Water was added to the mixture and organic layer was washed with water, brine, dried over NazS04, filtered and filtrated evaporated in vacuo to give the title compound as light yellowish solid (117.63 g, 97.6%). (M+H)+ = 214.1.
Example 32 B(OH)2 ~ S02NHtBu To a solution of compound of example 31 (53.25 g, 250 mmol) in THF (600 mL) in an ice bath, was added n-butyllithium in hexane (200 mL, 500 mmol) dropwise. A
thick precipitate was formed when the reaction mixture was warmed up to 10°C.
Triisopropylborate was added keeping the temperature below 35°C. After 1 hr., the mixture was cooled in an ice bath, 1N HCl (405 mL) was added, and the mixture was stirred overnight. The mixture was extracted with ether (100 mL) three times.
The combined organic extracts were extracted with 1N NaOH (130 mL) three times.
The aqueous extracts were acidified to pH 1 with 12 N HCI, and then extracted with ether three times (140 ML). The combined ether extracts were dried over MgS04, and solvents evaporated in vacuo. Hexane and ether were added and a white precipitate formed. The solid was collected and washed with 10% ether/hexane to give the title compound. (M+H)+ = 257.1.
Exam 1p a 33 S02NHtBu H2N ~
To a solution of compound of example 32 (6.4 g, 25 mmol) in toluene (120 mL) was added water (15 mL), SN NaOH solution (38.5 mL), isopropanol (60 mL), 4-bromoaniline and tetrakis(triphenylphosphine) palladium(0). The mixture was refluxed for six hours, cooled to room temperature, diluted with EtOAc. The organic layer was washed with water, dried with MgS04, filtered and concentrated.

This was purified by silica gel column chromatography using solvent system 30%
EtOAc in hexane as eluant to give the title compound (5g, 66%). ES-MS (M+H)+ _ 305.1.
Example 34 O O S02NHtBu I - -N ''~~~NH
i CN
To a solution of compound of example 33 (278 mg, 0.92 mmol) in DCM (5 mL) was added trimethylaluminum (1.37 mL, 2 M in hexane) dropwise. The reaction mixture was stirred at room temperature for 30 min. Compound of example 17 (236 mg, 0.92 mmol) in DCM (3 mL) was added dropwise. The mixture was stirred at room temperature overnight. 2N HCl was added to PH 2 to neutralize excess AlMe3.
Water and DCM were added. The organic layer was dried over MgS04 and concentrated in vacuo. The obtained resudue was purified by silica gel column chromatography using solvent system 50% EtOAc in hexane as eluant to give the title compound. ES-MS (M+Na)+ =553.2.
E~ 1ne35 - -N ,''~NH

A solution of the compound of example 34(96 mg, 0.18 mmol) in MeOH (3 mL) was treated with a stream of HCl gas for 10 min. at 0°C. The resulting solution was capped, stirred at room temperature overnight and evaporated in vacuo. The residue was reconstituted in MeOH (3 mL) and the mixture was treated with NH40Ac (69 mg, 0.9 mmol). The reaction mixture was refluxed for 1.5 hrs. and concentrated in vacuo. The obtained residue was purified by RP-HPLC to give the title compound as a white powder. ES-MS (M+H)+ = 492.0 BIOLOGICAL ACTNITY EXAMPLES
Evaluation of the compounds of this invention is guided by in vitro protease activity assays (see below) and in vivo studies to evaluate antithrombotic efficacy, and effects on hemostasis and hematological parameters.
The compounds of the present invention are dissolved in buffer to give solutions containing concentrations such that assay concentrations range from 0 to 100 pM. In the assays for thrombin, prothrombinase and factor Xa, a synthetic chromogenic substrate is added to a solution containing test compound and the enzyme of interest and the residual catalytic activity of that enzyme is determined spectrophotometrically. The IC50 of a compound is determined from the substrate turnover. The IC50 is the concentration of test compound giving 50% inhibition of the substrate turnover. The compounds of the present invention desirably have an ICSp of less than 500 nM in the factor Xa assay, preferably less than 200 nM, and more preferred compounds have an IC50 of about 100 nM or less in the factor Xa assay. The compounds of the present invention desirably have an IC50 of less than 4.0 pM in the prothrombinase assay, preferably less than 200 nM, and more preferred compounds have an IC50 of about 10 nM or less in the prothrombinase assay. The compounds of the present Invention desirably have an ICSO of greater than 1.0 pM in the thrombin assay, preferably greater than 10.0 ~,M, and more preferred compounds have an IC50 of greater than 100.0 ~M in the thrombin assay.

Amidol, is Assays for determining_protease inhibition activity The factor Xa and thrombin assays are performed at room temperature, in 0.02 M Tris~HCl buffer, pH 7.5, containing 0.15 M NaCI. The rates of hydrolysis of the para-nitroanilide substrate S-2765 (Chromogenix) for factor Xa, and the substrate Chromozym TH (Boehringer Mannheim) for thrombin following preincubation of the enzyme with inhibitor for 5 minutes at room temperature, and were determined using the Softmax 96-well plate reader (Molecular Devices), monitored at 405 nm to measure the time dependent appearance of p-nitroaniline.
The prothrombinase inhibition assay is performed in a plasma free system with modifications to the method described by Sinha, U. et al., Thromb. Res., Z, 427-436 (1994). Specifically, the activity of the prothrombinase complex is determined by measuring the time course of thrombin generation using the p-nitroanilide substrate Chromozym TH. The assay consists of preincubation ( 5 minutes) of selected compounds to be tested as inhibitors with the complex formed from factor Xa (0.5 nM), factor Va (2 nM), phosphatidyl serine:phosphatidyl choline (25:75, 20 ~,M) in 20 mM Tris~HCl buffer, pH 7.5, containing 0.15 M NaCI, 5 mM
CaCl2 and 0.1% bovine serum albumin. Aliquots from the complex-inhibitor mixture are added to prothrombin (1 nM) and Chromozym TH (0.1 mM). The rate of substrate cleavage is monitored at 405 nm for two minutes. Eight different concentrations of inhibitor are assayed in duplicate. A standard curve of thrombin generation by an equivalent amount of untreated complex are used for determination of percent inhibition.
Antithrombotic Efficacy in a Rabbit Model of Venous Thrombosis A rabbit deep vein thrombosis model as described by Hollenbach, S. et al., Thromb. Haemost. 71, 357-362 (1994), is used to determine the in-vivo antithrombotic activity of the test compounds. Rabbits are anesthetized with LM. injections of Ketamine, Xylazine, and Acepromazine cocktail. A standardized protocol consists of insertion of a thrombogenic cotton thread and copper wire apparatus into the abdominal vena cava of the anesthetized rabbit. A non-occlusive thrombus is allowed to develop in the central venous circulation and inhibition of thrombus growth is used as a measure of the S antithrombotic activity of the studied compounds. Test agents or control saline are administered through a marginal ear vein catheter. A femoral vein catheter is used for blood sampling prior to and during steady state infusion of test compound.
Initiation of thrombus formation begins immediately after advancement of the cotton thread apparatus into the central venous circulation. Test compounds are administered from time = 30 min to time = 150 min at which the experiment is terminated. The rabbits are euthanized and the thrombus excised by surgical dissection and characterized by weight and histology.
Blood samples are analyzed for changes in hematological and coagulation parameters.
Effects of Compounds in Rabbit Venous Thrombosis model Administration of compounds in the rabbit venous thrombosis model demonstrates antithrombotic efficacy at the higher doses evaluated. There are no significant effects of the compound on the aPTT and PT prolongation with the highest dose (100 pg/kg + 2.57 pg/kg/min). Compounds have no significant effects on hematological parameters as compared to saline controls. All measurements are an average of all samples after steady state administration of vehicle or (D)-Arg-Gly-Arg-thiazole. Values are expressed as mean + SD.
Without further description, it is believed that one of ordinary skill in the art can, using the preceding description and the following illustrative examples, make and utilize the compounds of the present invention and practice the claimed methods.

Claims (20)

WHAT IS CLAIMED IS:
1. A compound according to the formula I:
A-Y-D-E-G-J-Z-L
wherein:
A is selected from:
(a) C1-C6-alkyl;
(b) C3-C8-cycloalkyl;
(c) phenyl, which is independently substituted with 0-2 R1 subsituents;
(d) naphthyl, which is independently substituted with 0-2 R1- subsituents;and (e) a monocyclic or fused bicyclic heterocyclic ring system having from 5 to ring atoms, wherein 1-4 ring atoms of the ring system are selected from N, O and S, and wherein the ring system may be substituted with 0-2 R1 subsituents;
R1 is selected from:
Halo, C1-4alkyl, C2-6alkenyl, C2-6alkynyl, C3-8cycloalkyl, C0-4alkylC3-8cycloalkyl,-CN, -NO2, (CH2)m NR2R3, SO2NR2R3, SO2R2, CF3, OR2, and a 5-6 membered aromatic heterocyclic system containing from 1-4 heteroatoms selected from N, O and S, wherein from 1-4 hydrogen atoms on the aromatic heterocyclic system may be independently replaced with a member selected from the group consisting of halo, C1-C4 alkyl, -CN C1-4alkyl, C2-6alkenyl, C2-6alkynyl, C3-8cycloalkyl, C0-4alkylC3-8cycloalkyl and -NO2;
R2 and R3 are independently selected from the group consisting of H, C1-4alkyl, C2-6balkenyl, C2-6alkynyl, C3-8cycloalkyl, C0-4alkylC3-8cycloalkyl, C0-4alkylphenyl and C0-4alkylnaphthyl, wherein from 1-4 hydrogen atoms on the ring atoms of the phenyl and naphthyl moieties may be independently replaced with a member selected from the group consisting of halo, C1-4alkyl, C2-6alkenyl, C2-6alkynyl, C3-8cycloalkyl, C0-4alkylC3-8cycloalkyl, -CN, and -NO2;
m is an integer of 0-2;

Y is a member selected from the group consisting of:
a direct link, -C(=O)-, -N(R4)-, -C(=O)-N(R4)-, -N(R4)-C(=O)-, -SO2-, -O-, -SO2-N(R4)- and N(R4)-SO2-;
R4 is selected from:
H, C1-4alkyl, C2-6alkenyl, C2-6alkynyl, C32-8cycloalkyl, C0-4alkylC3-8cycloalkyl, C0-4alkylphenyl and C0-4alkylnaphthyl, wherein from 1-4 hydrogen atoms on the ring atoms of the phenyl and naphthyl moieties may be independently replaced with a member selected from the group consisting of halo, C1-4alkyl, C2-46alkenyl, C2-6alkynyl, C3-8cycloalkyl, C0-4alkylC3-8acycloalkyl, -CN, and -NO2;.
D is a direct link or is a member selected from the group consisting of:
(a) phenyl, which is independently substituted with 0-2 R1a subsituents;
(b) naphthyl, which is independently substituted with 0-2 R1a subsituents;
and (c) a monocyclic or fused bicyclic heterocyclic ring system having from 5 to ring atoms, wherein 1-4 ring atoms of the ring system are selected from N, O and S, and wherein the ring system may be substituted with 0-2 R1a subsituents;
R1a is selected from:
Halo, C1-4alkyl, C2-6alkenyl, C2-6alkynyl, C3-8cycloalkyl, C0-4alkylC3-8cycloalkyl, -CN, -NO2, (CH2)m NR2aR3a, SO2NR2aR3a, SO2R2a, CF3, OR2a, and a 5-6 membered aromatic heterocyclic system containing from 1-4 heteroatoms selected from N, O and S, wherein from 1-4 hydrogen atoms on the aromatic heterocyclic system may be independently replaced with a member selected from the group consisting of halo, C1-4alkyl, C2-6alkenyl, C2-6alkynyl, C3-8cycloalkyl, C0-4alky1C3-8cycloalkyl, -CN and -NO2;
R2a and R3a are independently selected from the group consisting of H, C1-4alkyl, C2-6alkenyl, C2-6alkynyl, C3-8cycloalkyl, C0-4alkylC3-8cycloalkyl, C0-4alkylphenyl and C0-4alkylnaphthyl, wherein from 1-4 hydrogen atoms on the ring atoms of the phenyl and naphthyl moieties may be independently replaced with a member selected from the group consisting of halo, C1-4alkyl, C2-6alkenyl, C2-6alkynyl, C3-8cycloalkyl, C0-4alkylC3-8cycloalkyl, -CN and -NO2;

E is a member selected from the group consisting of:

-N(R5)-C(=O)-, -C(=O)-N(R5)-, -N(R5)-C(=O)-N(R6)-, -SO2-N(R5)-, -N(R5)-SO2-N(R6)- and -N(R5)-SO2-N(R6)-C(=O)-;

R5 and R6 are independently selected from:

H, C1-4alkyl, C2-6alkenyl, C2-6alkynyl, C3-8cycloalkyl, C0-4alkylC3-8cycloalkyl, C0-4alkylphenyl, C0-4alkylnaphthyl, C0-4alkylheteroaryl, C1-4alkylCOOH and C1-4alkylCOOC1-4alkyl, wherein from 1-4 hydrogen atoms on the ring atoms of the phenyl, naphthyl and heteroaryl moieties may be independently replaced with a member selected from the group consisting of halo, C1-4alkyl, C2-6alkenyl, C2-6alkynyl, C3-8cycloalkyl, C0-4alkylC3-8cycloalkyl, -CN and -NO2;

G is a member selected from the group consisting of from:

a direct link, -CR7R8- and -CR7a R8a-CR7a R8b-wherein R7, R8, R7a, R8a, R7b and R8b are independently a member selected from from the group consisting of:

hydrogen, C1-4alkyl, C2-6alkenyl, C2-6alkynyl, C3-8cycloalkyl, C0-4alkyl-C3-8cycloalkyl, C0-4alkylphenyl, C0-4alkylnaphthyl, -OR9, -C0-4alkylCOOR9, -C0-4alkylC(=O)NR9R10, -C0-4,alkylC(=O)NR9-CH2-CH2-O-R10, -C0-4alkylC(=O)NR9(-CH2CH2-O-R10-)2, -N(R9)COR10, -N(R9)C(=O)R10, -N(R9)SO2R10, and a naturally occuring or synthetic amino acid side chain, wherein from 1-4 hydrogen atoms on the ring atoms of the phenyl and naphthyl moieties may be independently replaced with a member selected from the group consisting of halo, C1-4alkyl, C2-6alkenyl, C2-6alkynyl, C3-8cycloalkyl, C0-4alkyl-C3-8cycloalkyl, -CN and -NO2;

R9 and R10 are independently selected from:

H, C1-4alkyl, C0-4alkylphenyl and C0-4alkylnaphthyl, wherein from 1-4 hydrogen atoms on the ring atoms of the phenyl and naphthyl moieties may be independently replaced with a member selected from the group consisting of halo, C1-4alkyl, C2-6alkenyl, C2-6alkynyl, C3-8cycloalkyl, C0-4alkyl-C3-8cycloalkyl, -CN and -NO2, and wherein R9 and R10 taken together can form a 5-8 membered heterocylic ring;
J is a member selected from the group consisting of:
wherein the ring carbons or the second ring nitrogen of the amino ring structure and/or the ring carbons on the alkylene bridging groups attached to the amino ring structure may be independently substituted by a total of 0 to 4 R11, R11a, R11b and R11c groups;
R11, R11a, R11b and R11c are independently a member selected from the group consisting of:
hydrogen, -OH, -O-C1-4alkyl, -C1-4alkyl, C2-6alkenyl, C2-6alkynyl, C3-8cycloalkyl, C0-4alkyl-C3-8cycloalkyl, C0-4alkylphenyl, C0-4alkylnaphthyl, C0-4alkylheterocyclic ring having from 1 to 4 hetero ring atoms selected from the group consisting of N, O and S, CH2COOC1-4alkyl, CH2COOC1-4alkylphenyl and CH2COOC1-4alkylnaphthyl;
Z is a member selected from the group consisting of:
(a) phenyl, which is independently substituted with 0-2 R1b subsituents;
(b) naphthyl, which is independently substituted with 0-2 R1b subsituents;
and (c) a monocyclic or fused bicyclic heterocyclic ring system having from 5 to ring atoms, wherein 1-4 ring atoms of the ring system are selected from N, O and S, and wherein the ring system may be substituted with 0-2 R1b subsituents;
R1b is selected from:

Halo, C1-4alkyl, C2-6alkenyl, C2-6alkynyl, C3-8cycloalkyl, C0-4alkylC3-8cycloalkyl, -CN, -NO2, NR2b R3b, SO2NR2b R3b, SO2R2b, CF3, OR2b, O-CH2-CH2-OR2b, O-CH2 COOR2b, N(R2b)-CH2-CH2-OR2b, N(-CH2-CH2-OR 2b)2, N(R2b)-C(=O)R3b, N(R2b)-SO2-R3b, and a 5-6 membered aromatic heterocyclic system containing from 1-4 heteroatoms selected from N, O and S, wherein from 1-4 hydrogen atoms on the aromatic heterocyclic system may be independently replaced with a member selected from the group consisting of halo, C1-4alkyl, C2-6alkenyl, C2-6alkynyl, C3-8cycloalkyl, C0-4alkylC3-8cycloalkyl, -CN and -NO2;
R2b and R3b are independently selected from the group consisting of:
H, C1-4alkyl, C2-6alkenyl, C2-6alkynyl, C3-8cycloalkyl, C0-4alkylC3-8cycloalkyl, C0-4alkylphenyl and C0-4alkylnaphthyl, wherein from 1-4 hydrogen atoms on the ring atoms of the phenyl and naphthyl moieties may be independently replaced with a member selected from the group consisting of halo, C1-4alkyl, C2-6alkenyl, C2-6alkynyl, C3-8cycloalkyl, C0-4alkylC3-8cycloalkyl, -CN and -NO2;
L is selected from:
H, -CN, C(-O)N12R13, (CH2)n NR12R13, C(-NR12)NR12R13, NR12R13, OR12, -NR12C(=NR12)NR12R13, and NR12C(=NR12)-R13;

R12 and R13 are independently selected from:
hydrogen, -OR14, -NR14R15, C1-4alkyl, C0-4alkylphenyl, C0-4alkylnaphthyl, COOC1-4alkyl, COO-C0-4alkylphenyl and COO-C0-4alkylnaphthyl, wherein from 1-4 hydrogen atoms on the ring atoms of the phenyl and naphthyl moieties may be independently replaced with a member selected from the group consisting of halo, C1-4alkyl, C2-6alkenyl, C2-6alkynyl, C3-8cycloalkyl, C0-4 alkylC3-8cycloalkyl, -CN, and -NO2;

R14 and R15 are independently selected from:
H, C1-4alkyl, C2-6alkenyl, C2-6alkynyl, C3-8cycloalkyl, C0-4alkylC3-8cycloalkyl, C0-4alkylphenyl and C0-4alkylnaphthyl, wherein from 1-4 hydrogen atoms on the ring atoms of the phenyl and naphthyl moieties may be independently replaced with a member selected from the group consisting of halo, C1-4alkyl, C2-6alkenyl, C2-6alkynyl, C3-8cycloalkyl, C0-4alkylC3-8cycloalkyl, -CN, and -NO2;
and all pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives thereof.
2. ~A compound of claim 1, wherein:
A is selected from:
(a) C1-C6 alkyl;
(b) C3-C8 cycloalkyl;
(c) phenyl, which is independently substituted with 0-2 R1 subsituents;~
(d) naphthyl, which is independently substituted with 0-2 R1 subsituents; and (e) a monocyclic or fused bicyclic heterocyclic ring system having from 5 to ring atoms, wherein 1-4 ring atoms of the ring system are selected from N, O and S, and wherein the ring system may be substituted with 0-2 R1 subsituents;
R1 is selected from:
halo, C1-4alkyl, -CN, (CH2)m NR2R3, SO2NR2R3, SO2R2, CF3, OR2, and a 5-6 membered aromatic heterocyclic system containing from 1-4 heteroatoms selected from N, O and S;
R2 and R3 are independently selected from the group consisting of:
H, C1-4alkyl and C0-4alkylaryl, m is an integer of 0-2;
Y is a member selected from the group consisting of:
a direct link, -C(=O)-, -N(R4)-, -C(=O)-N(R4)-, -N(R4)-C(=O)-, -SO2-, -O-, -SO2N(R4)- and N(R4)-SO2;
R4 is selected from:
H, C1-4alkyl and C0-4alkylaryl;

D is absent or is a member selected from the group consisting of:
(a) aryl, which is independently substituted with 0-2 R1a subsituents; and (b) a monocyclic or fused bicyclic heterocyclic ring system having from 5 to ring atoms, wherein 1-4 ring atoms of the ring system are selected from N, O and S, and wherein the ring system may be substituted with 0-2 R1a subsituents;
R1a is selected from:
Halo, C1-4alkyl, -CN, -NO2, (CH2)m NR2a R3a, SO2NR2a R3a, SO2R2a, CF3, OR2a, and a 5-6 membered aromatic heterocyclic ring containing from 1-4 heteroatoms selected from N, O and S;
R2a and R3a are independently selected from the group consisting of:
H, C1-4alkyl and C0-4alkylaryl;
E is a member selected from the group consisting of:
-N(R5)-C(=O)-, -C(=O)-N(R5)-, -N(R5)-C(=O)-N(R6)-, -SO2N(R5)-, -N(R5)-SO2-N(R6)- and -N(R5)-SO2-N(R6)-C(=O)-;
R5 and R6 are independently selected from:
H, C1-4alkyl, C0-4alkylaryl, C0-4alkylheteroaryl, C1-4alkylCOOH and C1-4alkylCOOC1-4alkyl;
G is a member selected from the group consisting of:
a direct link, -CR7R8- and -CR7a R8a -CR7a R8b-wherein R7, R8, R7a, R8a, R7b and R8b are independently a member selected from from the group consisting of:
hydrogen, C1-4alkyl, C0-4alkyl-C3-8cycloalkyl, C0-4alkylaryl, -OR9, -C0-4alkylCOOR9, -C0-4alkylC(=O)NR9R10, -N(R9)COR10, -N(R9)C(=O)R10, -N(R9)SO2R10, and common amino acid side chains;
R9 and R10 are independently selected from:
H, C1-4alkyl and C0-4alkylaryl;

J is a member selected from the group consisting of:
wherein the ring carbons or the second ring nitrogen of the amino ring structure and/or the ring carbons on the alkylene bridging groups attached to the amino ring structure may be independently substituted by a total of 0 to 4 R11, R11a, R11b and R11c groups;
R11, R11a, R11b and R11c are independently a member selected from the group consisting of:
hydrogen, -OH, -O-C1-4alkyl, -C1-4alkyl, C2-6alkenyl, C2-6alkynyl, C3-8cycloalkyl, C0-4alkyl-C3-8cycloalkyl, C0-4alkylphenyl, C0-4alkylnaphthyl, C0-4alkylheterocyclic ring having from 1 to 4 hetero ring atoms selected from the group consisting of N, O and S, CH2COOC1-4alkyl, CH2COOC1-4alkylphenyl and CH2COOC1-4alkylnaphthyl;
Z is a member selected from the group consisting of:
(a) aryl, which is independently substituted with 0-2 R1b subsituents;and (b) a monocyclic or fused bicyclic heterocyclic ring system having from 5 to ring atoms, wherein 1-4 ring atoms of the ring system are selected from N, O and S, and wherein the ring system may be substituted with 0-2 R1b subsituents;
R1b is selected from:
halo, C1-4alkyl, -CN, -NO2, NR2b R3b, SO2NR2b R3b, SO2R2b, CF3, OR2b, O-CH2-CH2-OR2b, O-CH2-COOR2b, N(R2b)-CH2-CH2-OR2b, N(-CH2-CH2-OR2b)2, N(R2b)-C(=O)R3b, N(R2b)-SO2-R3b, and a 5-6 membered aromatic heterocyclic ring containing from 1-4 heteroatoms selected from N, O and S;
R2b and R3b are independently selected from the group consisting of:
H, C1-4alkyl and C0-4alkylaryl;

L is selected from:
H, -CN, C(=O)NR12R13, (CH2)n NR12R13,C(=NR12)NR12R13, NR12R13, OR12, -NR12C(=NR12)NR12R13 and NR12C(=NR12)-R13;
R12 and R13 are independently selected from:
hydrogen, -OR14, -NR14R15, C1-4alkyl, C0-4alkylaryl COOC1-4alkyl, and COO-C0-4alkylaryl; and R14 and R15 are independently selected from:
H and C1-4alkyl.
3. A compound of claim 1, wherein:
A is selected from:
(a) phenyl, which is independently substituted with 0-2 R1 subsituents; and (b) a monocyclic or fused bicyclic heterocyclic ring system having from 5 to ring atoms, wherein 1-4 ring atoms of the ring system are selected from N, O and S, and wherein the ring system may be substituted with 0-2 R1 subsituents;
R1 is selected from:
halo, (CH2)m NR2R3, SO2NR2R3 and SO2R2;
R2 and R3 are independently selected from the group consisting of:
H and C1-4alkyl;
Y is a member selected from the group consisting of:
a direct link, -C(=O)-, - SO2 and -O-;
D is a member selected from the group consisting of:
(a) phenyl, which is independently substituted with 0-2 R1a subsituents; and (b) a monocyclic or fused bicyclic heterocyclic ring system having from 5 to 10 ring atoms, wherein 1-4 ring atoms of the ring system are selected from N, O and S, and wherein the ring system may be substituted with 0-2 R1a subsituents;
R1a is selected from:
Halo and C1-4alkyl;
R2a and R3a are independently selected from the group consisting of:
H, C1-4alkyl, C0-4alkylaryl;
E is a member selected from the group consisting of:
-N(R5)-C(=O)- and -C(=O)-N(R5)-;
R5 and R6 are independently selected from:
H, C1-4alkyl, C0-4alkylaryl and C0-4alkylheteroaryl;
G is a member selected from the group consisting of:
a direct link, -CR7R8- and -CR7a R8a -CR7a R8b-wherein R7, R8, R7a, R8a, R7b, and R8b are independently a member selected from from the group consisting of:
hydrogen, C1-4alkyl, C0-4alkyl-C3-8cycloalkyl, C0-4alkylaryl, -OR9, -C0-4alkylCOOR9, -C0-4alkylC(=O) NR9R10, -C0-4alkylC(=O)NR9-CH2-CH2-O-R10, -C0-4alkylC(=O)NR9(-CH2-CH2-O-R10-)2, -N(R9)COR10, -N(R9)C(=O)R10, -N(R9)SO2R10, and common amino acid side chains;
R9 and R10 are independently selected from:
H and C1-4alkyl, wherein the NR9R10 group of R7, R8, R7a, R8a, R7b and R8b is optionally cyclized to form a 5-8 membered heterocyclic group;
J is a member selected from the group consisting of:
wherein the ring carbons or the second ring nitrogen of the amino ring structure may be substituted by a total of 0 to 2 R11 and R11c groups;
R11, R11a, R11b and R11c are independently a member selected from the group consisting of:
hydrogen, -OH, -O-C1-4alkyl, -C1-4alkyl, C2-6alkenyl, C0-4alkylaryl, and a C0-4alkylheterocyclic ring having from 1 to 4 hetero ring atoms selected from the group consisting of N, O and S;
Z is a member selected from the group consisting of:
(a) phenyl, which is independently substituted with 0-2 R1b subsituents;
(b) an aromatic heterocyclic ring having from 5 to 10 ring atoms, wherein 1-4 ring atoms are selected from N, O and S, and wherein the ring may be subsituted independently by from 0-2 R1b subsituents; and (c) a fused aromatic bicyclic heterocyclic ring system having from 5 to 10 ring atoms, wherein 1-4 ring atoms of the ring system are selected from N, O and S, wherein the bicyclic ring system may be substituted with 0-2 R1b subsituents;
R1b is selected from:
halo, C1-4,alkyl, OH, OBn, O-CH2-CH2-OH, O-CH2 CH2-OCH3, O-CH2-COOH, O-CH2 C(=O)-O-CH3, NH2, NH-CH2-CH2-O-CH3, NH-C =O)-O-CH3, and NH-SO2-CH3;
L is selected from:
H, C(=O)NR12R13, (CH2)n NR12R13 and C(=NR12)NR12R13; and R12 and R13 are independently selected from:
hydrogen and C1-4alkyl.
4. A compound of claim 1, wherein:

A is a member selected from the group consisting of:
D is a member selected from the group consisting of:
E is a member selected from the group consisting of:
-C(=O)-NH-, -C(=O)-N(-CH3)-, C(=O)-N(-Bn)-, -NH-C(=O)-, -N(-CH3)-C(=O)- and -N(-Bn)C(=O)-;
G is a member selected from the group consisting of:
a direct link, -CH-(-NH2)-CH2-, -CH-(-NH(C(=O)-CH3))-CH2-, -CH-(-NH(C(=O)-Ph))-CH2 , -CH-(C(=O)-OR8)-, -CH(-R7)-, -CH2-CH(C(=O)-OR8)-, and -CH2 CH(C(=O)-N(-R8, -R8))-;
R7 is a member selected from the group consisting of:
H, phenyl, Bn, -O-loweralkyl and cycohexyl;
R8 is a member selected from the group consisting of:
H, C1-6alkyl, -O-loweralkyl and C3-6cycloalkyl;

J is a member selected from the group consisting of:
wherein the second ring nitrogen of the amino ring structure may be substituted by a R11c group;
R11c is a member selected from the group consisting of:
H, methyl, phenyl and benzyl; and Z and L taken together are a member selected from the group consisting of:
5. ~A pharmaceutical composition for preventing or treating a condition in a mammal characterized by undesired thrombosis comprising a pharmaceutically acceptable carrier and a compound of claim 1.
6. A pharmaceutical composition for preventing or treating a condition in a mammal characterized by undesired thrombosis comprising a pharmaceutically acceptable carrier and a compound of claim 2.
7. A pharmaceutical composition for preventing or treating a condition in a mammal characterized by undesired thrombosis comprising a pharmaceutically acceptable carrier and a compound of claim 3.
8. A pharmaceutical composition for preventing or treating a condition in a mammal characterized by undesired thrombosis comprising a pharmaceutically acceptable carrier and a compound of claim 4.
9. A method for preventing or treating a condition in a mammal characterized by undesired thrombosis comprising the step of administering to said mammal a therapeutically effective amount of a compound of claim 1.
10. The method of claim 9, wherein the condition is selected from the group consisting of: acute coronary syndrome, myocardial infarction, unstable angina, refractory angina, occlusive coronary thrombus occurring post-thrombolytic therapy or post-coronary angioplasty, a thrombotically mediated cerebrovascular syndrome, embolic stroke, thrombotic stroke, transient ischemic attacks, venous thrombosis, deep venous thrombosis, pulmonary embolus, coagulopathy, disseminated intravascular coagulation, thrombotic thrombocytopenic purpura, thromboangiitis obliterans, thrombotic disease associated with heparin-induced thrombocytopenia, thrombotic complications associated with extracorporeal circulation, thrombotic complications associated with instrumentation such as cardiac or other intravascular catheterization, infra-aortic balloon pump, coronary stent or cardiac valve, and conditions requiring the fitting of prosthetic devices.
11. A method for preventing or treating a condition in a mammal characterized by undesired thrombosis comprising the step of administering to said mammal a therapeutically effective amount of a compound of claim 2.
12. The method of claim 11, wherein the condition is selected from the group consisting of acute coronary syndrome, myocardial infarction, unstable angina, refractory angina, occlusive coronary thrombus occurring post-thrombolytic therapy or post-coronary angioplasty, a thrombotically mediated cerebrovascular syndrome, embolic stroke, thrombotic stroke, transient ischemic attacks, venous thrombosis, deep venous thrombosis, pulmonary embolus, coagulopathy, disseminated intravascular coagulation, thrombotic thrombocytopenic purpura, thromboangiitis obliterans, thrombotic disease associated with heparin-induced thrombocytopenia, thrombotic complications associated with extracorporeal circulation, thrombotic complications associated with instrumentation such as cardiac or other intravascular catheterization, infra-aortic balloon pump, coronary stent or cardiac valve, and conditions requiring the fitting of prosthetic devices.
13. A method for preventing or treating a condition in a mammal characterized by undesired thrombosis comprising the step of administering to said mammal a therapeutically effective amount of a compound of claim 3.
14. The method of claim 13, wherein the condition is selected from the group consisting of acute coronary syndrome, myocardial infarction, unstable angina, refractory angina, occlusive coronary thrombus occurring post-thrombolytic therapy or post-coronary angioplasty, a thrombotically mediated cerebrovascular syndrome, embolic stroke, thrombotic stroke, transient ischemic attacks, venous thrombosis, deep venous thrombosis, pulmonary embolus, coagulopathy, disseminated intravascular coagulation, thrombotic thrombocytopenic purpura, thromboangiitis obliterans, thrombotic disease associated with heparin-induced thrombocytopenia, thrombotic complications associated with extracorporeal circulation, thrombotic complications associated with instrumentation such as cardiac or other intravascular catheterization, intra-aortic balloon pump, coronary stent or cardiac valve, and conditions requiring the fitting of prosthetic devices.
15. A method for preventing or treating a condition in a mammal characterized by undesired thrombosis comprising the step of administering to said mammal a therapeutically effective amount of a compound of claim 4.
16. The method of claim 15, wherein the condition is selected from the group consisting of acute coronary syndrome, myocardial infarction, unstable angina, refractory angina, occlusive coronary thrombus occurring post-thrombolytic therapy or post-coronary angioplasty, a thrombotically mediated cerebrovascular syndrome, embolic stroke, thrombotic stroke, transient ischemic attacks, venous thrombosis, deep venous thrombosis, pulmonary embolus, coagulopathy, disseminated intravascular coagulation, thrombotic thrombocytopenic purpura, thromboangiitis obliterans, thrombotic disease associated with heparin-induced thrombocytopenia, thrombotic complications associated with extracorporeal circulation, thrombotic complications associated with instrumentation such as cardiac or other intravascular catheterization, intra-aortic balloon pump, coronary stent or cardiac valve, and conditions requiring the fitting of prosthetic devices.
17. A method for inhibiting the coagulation of biological samples, comprising the administration of a compound of claim 1.
18. A method for inhibiting the coagulation of biological samples, comprising the administration of a compound of claim 2.
19. A method for inhibiting the coagulation of biological samples, comprising the administration of a compound of claim 3.
20. A method for inhibiting the coagulation of biological samples, comprising the administration of a compound of claim 4.
CA002374788A 1999-05-24 2000-05-24 Inhibitors of factor xa Abandoned CA2374788A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13583899P 1999-05-24 1999-05-24
US60/135,838 1999-05-24
PCT/US2000/014193 WO2000071515A2 (en) 1999-05-24 2000-05-24 INHIBITORS OF FACTOR Xa

Publications (1)

Publication Number Publication Date
CA2374788A1 true CA2374788A1 (en) 2000-11-30

Family

ID=22469944

Family Applications (2)

Application Number Title Priority Date Filing Date
CA002374788A Abandoned CA2374788A1 (en) 1999-05-24 2000-05-24 Inhibitors of factor xa
CA002371904A Abandoned CA2371904A1 (en) 1999-05-24 2000-05-24 Inhibitors of factor xa

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA002371904A Abandoned CA2371904A1 (en) 1999-05-24 2000-05-24 Inhibitors of factor xa

Country Status (5)

Country Link
EP (2) EP1185512A2 (en)
JP (2) JP2003500391A (en)
AU (2) AU5283600A (en)
CA (2) CA2374788A1 (en)
WO (2) WO2000071515A2 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010042042A (en) 1998-03-19 2001-05-25 에가시라 구니오 Aminoisoquinoline derivatives
TWI290136B (en) 2000-04-05 2007-11-21 Daiichi Seiyaku Co Ethylenediamine derivatives
WO2003000657A1 (en) 2001-06-20 2003-01-03 Daiichi Pharmaceutical Co., Ltd. Diamine derivatives
DE10139060A1 (en) 2001-08-08 2003-02-20 Merck Patent Gmbh New bicyclic benzene derivatives useful as factor Xa and VIIa inhibitors, e.g. for treating thrombosis, myocardial infarct, arteriosclerosis, inflammation, stroke, angina, restenosis and tumors
OA12790A (en) 2002-03-13 2006-07-10 Janssen Pharmaceutica Nv New inhibitors of histone deacetylase.
ATE398615T1 (en) 2002-03-13 2008-07-15 Janssen Pharmaceutica Nv PIPERAZINYL, PIPERIDINYL AND MORPHOLINYL DERIVATIVES AS NEW INHIBITORS OF HISTONE DEACETYLASE
ES2306858T3 (en) 2002-03-13 2008-11-16 Janssen Pharmaceutica Nv CARBONILAMINE DERIVATIVES AS NEW INHIBITORS OF HISTONADESACETILASAS.
PE20040167A1 (en) 2002-03-28 2004-05-26 Novartis Ag SULPHAMIC ACID AMIDES
DK1569912T3 (en) 2002-12-03 2015-06-29 Pharmacyclics Inc 2- (2-hydroxybiphenyl-3-yl) -1h-benzoimidazole-5-carboxamidine derivatives as factor VIIa inhibitors.
AU2004226278B2 (en) * 2003-04-03 2010-07-29 Merck Patent Gmbh Pyrrolidino-1,2-dicarboxy-1-(phenylamide)-2-(4-(3-oxo-morpholino-4-yl)-phenylamide) derivatives and related compounds for use as inhibitors of coagulation factor Xa in the treatment of thrombo-embolic diseases
PL2256106T3 (en) 2003-07-22 2015-08-31 Astex Therapeutics Ltd 3,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinases (CDK) and glycogen synthase kinase-3 (GSK-3) modulators
DE102004014945A1 (en) * 2004-03-26 2005-10-13 Merck Patent Gmbh Prolinylderivate
WO2006010750A1 (en) 2004-07-28 2006-02-02 Janssen Pharmaceutica N.V. Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase
US8404718B2 (en) 2005-01-21 2013-03-26 Astex Therapeutics Limited Combinations of pyrazole kinase inhibitors
AR054425A1 (en) 2005-01-21 2007-06-27 Astex Therapeutics Ltd PIPERIDIN ADDITION SALTS 4-IL-ACID AMID 4- (2,6-DICLORO-BENZOILAMINO) 1H-PIRAZOL-3-CARBOXILICO.
WO2007082874A1 (en) 2006-01-19 2007-07-26 Janssen Pharmaceutica N.V. Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
EP3541381B1 (en) * 2016-11-18 2022-12-28 Merck Sharp & Dohme LLC Inhibitors of factor xiia
MX2022001863A (en) 2019-08-12 2022-05-30 Deciphera Pharmaceuticals Llc Ripretinib for treating gastrointestinal stromal tumors.
WO2021030405A1 (en) 2019-08-12 2021-02-18 Deciphera Pharmaceuticals, Llc Ripretinib for treating gastrointestinal stromal tumors
RS65058B1 (en) 2019-12-30 2024-02-29 Deciphera Pharmaceuticals Llc Amorphous kinase inhibitor formulations and methods of use thereof
BR112022013169A2 (en) 2019-12-30 2022-09-13 Deciphera Pharmaceuticals Llc COMPOSITIONS OF 1-(4-BROMO-5-(1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAFTIRIDIN-3-YL)-2-FLUOROFEYL)-3- PHENYLUREA
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000516234A (en) * 1996-08-16 2000-12-05 デュポン ファーマシューティカルズ カンパニー Amidinophenyl-pyrrolidines, amidinophenyl-pyrrolines, and amidinophenyl-isoxazolidines and derivatives thereof
WO1998028269A1 (en) * 1996-12-23 1998-07-02 Du Pont Pharmaceuticals Company NITROGEN CONTAINING HETEROAROMATICS AS FACTOR Xa INHIBITORS

Also Published As

Publication number Publication date
JP2003500391A (en) 2003-01-07
WO2000071516A3 (en) 2001-01-18
WO2000071516B1 (en) 2001-03-01
EP1185511A2 (en) 2002-03-13
AU5284000A (en) 2000-12-12
WO2000071515A2 (en) 2000-11-30
CA2371904A1 (en) 2000-11-30
JP2003500390A (en) 2003-01-07
EP1185512A2 (en) 2002-03-13
WO2000071515A3 (en) 2001-01-25
AU5283600A (en) 2000-12-12
WO2000071516A2 (en) 2000-11-30

Similar Documents

Publication Publication Date Title
US6638980B1 (en) Inhibitors of factor Xa
US6545055B1 (en) Inhibitors of factor Xa
CA2374788A1 (en) Inhibitors of factor xa
US6632815B2 (en) Inhibitors of factor Xa
US20030114448A1 (en) Inhibitors of factor Xa
WO2001012600A1 (en) INHIBITORS OF FACTOR Xa
EP1183234A1 (en) INHIBITORS OF FACTOR Xa
US6686368B1 (en) Inhibitors of factor Xa
WO2002079145A1 (en) BENZAMIDE INHIBITORS OF FACTOR Xa
US20040082786A1 (en) Piperazine based inhibitors of factor xa
CA2392576A1 (en) .beta.-amino acid-, aspartic acid- and diaminopropionic-based inhibitors of factor xa
US6673817B1 (en) Inhibitors of factor Xa
US20040077690A1 (en) Quaternary amidino based inhibitors of factor xa
WO2002026718A2 (en) Bicyclic pyrimidin-4-one based inhibitors of factor xa
EP1322643A1 (en) Piperazin-2-one amides as inhibitors of factor xa
WO2001072725A1 (en) BICYCLIC SULFONYL AMINO INHIBITORS OF FACTOR Xa

Legal Events

Date Code Title Description
FZDE Dead